Manifolds, systems, and methods for administering reduced pressure to a subcutaneous tissue site

ABSTRACT

Systems, methods, and apparatuses are provided for delivering reduced pressure to a subcutaneous tissue site, such as a bone tissue site. In one instance, a manifold for providing reduced pressure to a subcutaneous tissue includes a longitudinal manifold body formed with at least one purging lumen and a reduced-pressure lumen. The manifold further includes a plurality of manifolding surface features or slits formed on the second, tissue-facing side of the longitudinal manifold body and a plurality of apertures formed in the longitudinal manifold body on the second, tissue-facing side. The plurality of apertures fluidly couple the reduced-pressure lumen and the manifolding surface features or slits. The manifold further includes an end cap fluidly coupling the reduced-pressure lumen and the at least one purging lumen. Other systems, apparatuses, and methods are presented.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No.12/647,146, filed Dec. 24, 2009, which is a continuation-in-part of U.S.patent application Ser. No. 12/540,934, filed Aug. 13, 2009, acontinuation-in-part of U.S. patent application Ser. No. 11/807,834,filed May 29, 2007, a continuation in part of U.S. patent applicationSer. No. 11/724,072, filed Mar. 13, 2007, and claims the benefit, under35 USC § 119(e), of the filing of U.S. Provisional Patent ApplicationSer. No. 61/141,728, filed Dec. 31, 2008. U.S. patent application Ser.No. 12/540,934, filed Aug. 13, 2009 is a continuation-in-part of U.S.patent application Ser. No. 11/807,834, filed May 29, 2007, and acontinuation-in-part of U.S. patent application Ser. No. 11/724,072,filed on Mar. 13, 2007. U.S. patent application Ser. No. 11/807,834,filed May 29, 2007 is a continuation-in-part of U.S. patent applicationSer. No. 11/724,072, filed Mar. 13, 2007, and claims the benefit of U.S.Provisional Application Ser. No. 60/782,171, filed Mar. 14, 2006. U.S.patent application Ser. No. 11/724,072, filed Mar. 13, 2007, claims thebenefit of U.S. Provisional Application Ser. No. 60/782,171. The presentapplication also. All of the above-referenced applications are herebyincorporated by reference for all purposes.

BACKGROUND OF THE INVENTION

The illustrative embodiments relate generally to systems, apparatuses,and methods of promoting tissue growth and more specifically a systemfor applying reduced-pressure tissue treatment to a tissue site, such asa bone.

Reduced-pressure therapy is increasingly used to promote wound healingin soft tissue wounds that are slow to heal or non-healing withoutreduced-pressure therapy. Typically, reduced pressure is applied to thewound site through an open-cell foam or other device that serves as amanifold to distribute the reduced pressure. The open-cell foam is sizedto fit the existing wound, placed into contact with the wound, and thenperiodically replaced with smaller pieces of foam as the wound begins toheal and become smaller. Frequent replacement of the open-cell foam maybe necessary to minimize the amount of tissue that grows into the cellsof the foam. Significant tissue in-growth can cause pain to patientsduring removal of the foam.

Reduced-pressure therapy may be applied to non-healing, open wounds. Insome cases, the tissues being healed are subcutaneous, and in othercases, the tissues are located within or on dermal tissue.Traditionally, reduced-pressure therapy has primarily been applied tosoft tissues. Reduced-pressure therapy has not typically been used totreat closed, deep-tissue wounds because of the difficulty of accesspresented by such wounds. Additionally, reduced-pressure therapy has notgenerally been used in connection with healing bone defects or promotingbone growth, primarily due to access problems.

BRIEF SUMMARY

To alleviate the existing problems with reduced-pressure treatmentsystems, the illustrative embodiments described herein are directed to asystems, methods, and apparatuses for applying a reduced pressure to asubcutaneous tissue site. An apparatus includes a manifold that isadapted to be inserted for placement at the subcutaneous tissue site.The manifold may include at least one purging lumen operable to delivera fluid to a distal portion of the manifold. The manifold may alsoinclude at least one slit at the distal portion of the manifold. Themanifold may include at least one reduced-pressure lumen operable todeliver reduced pressure to the subcutaneous tissue site via the atleast one slit. In one example, the manifold also includes an interlumenchannel fluidly interconnecting the at least one purging lumen, the atleast one reduced-pressure lumen, and the at least one slit at thedistal portion of the manifold.

According to one illustrative embodiment, a system for applying areduced pressure at a subcutaneous tissue site is also provided. Thesystem includes a reduced-pressure source operable to supply reducedpressure to a manifold. The manifold may include at least onereduced-pressure lumen operable to deliver reduced pressure suppliedfrom the reduced-pressure source to the subcutaneous tissue site via atleast one slit. The system may also include a delivery tube in fluidcommunication with the manifold and the reduced pressure source todeliver reduced pressure to the at least one reduced-pressure lumen. Thedelivery tube may also provide for the delivery of fluid to the at leastone purge lumen.

According to one illustrative embodiment, a method for applying areduced pressure at a subcutaneous tissue site is also provided. Themethod may include applying a manifold to the subcutaneous tissue site.The method may also include supplying a reduced pressure to the manifoldvia a delivery tube.

According to one illustrative embodiment, a method of manufacturing anapparatus for applying a reduced pressure at a subcutaneous tissue siteon a patient is also provided. The method may include forming a manifoldadapted to be inserted into the patient and for placement at thesubcutaneous tissue site. In one example, the method may also includeproviding a delivery tube for delivering reduced pressure to at leastone reduced-pressure lumen in the manifold and fluid to at least onepurge lumen in the manifold. In this example, the method may alsoinclude coupling the delivery tube to the manifold such that thedelivery tube is in fluid communication with the manifold.

According to another illustrative embodiment, a manifold for providingreduced pressure to a subcutaneous tissue site on a patient includes alongitudinal manifold body formed with at least one purging lumen and areduced-pressure lumen. The manifold body has a first side and a second,tissue-facing side. The manifold further includes a plurality ofmanifolding surface features formed on the second, tissue-facing side ofthe longitudinal manifold body and a plurality of apertures formed inthe longitudinal manifold body on the second, tissue-facing side. Theplurality of apertures fluidly couple the reduced-pressure lumen and themanifolding surface features. The manifold further includes an end capfluidly coupling the reduced-pressure lumen and the at least one purginglumen.

According to another illustrative embodiment, a system for treating asubcutaneous tissue site on a patient with reduced pressure includes areduced-pressure source, a manifold, and a reduced pressure deliverytube coupling the reduced-pressure source and the manifold. The manifoldincludes a longitudinal manifold body formed with at least one purginglumen and a reduced-pressure lumen. The manifold body has a first sideand a second, tissue-facing side. The manifold further includes aplurality of manifolding surface features formed on the second,tissue-facing side of the longitudinal manifold body and a plurality ofapertures formed in the longitudinal manifold body on the second,tissue-facing side. The plurality of apertures fluidly couple thereduced-pressure lumen and the manifolding surface features. Themanifold further includes an end cap fluidly coupling thereduced-pressure lumen and the at least one purging lumen.

According to another illustrative embodiment, a method of manufacturinga manifold for providing reduced pressure to a subcutaneous tissue siteon a patient includes forming a longitudinal manifold body with at leastone purging lumen and a reduced-pressure lumen. The manifold body has afirst side and a second, tissue-facing side. The method further includesforming a plurality of manifolding surface features on the second,tissue-facing side of the longitudinal manifold body and forming aplurality of apertures in the longitudinal manifold body on the second,tissue-facing side. The plurality of apertures fluidly couple thereduced-pressure lumen and the manifolding surface features. The methodfurther includes forming an end cap on the manifold body that fluidlycouples the reduced-pressure lumen and the at least one purging lumen.

According to an illustrative, non-limiting embodiment, a system forapplying reduced pressure to a subcutaneous tissue site that includes areduced-pressure source for supplying reduced pressure, a fluid sourcefor supplying a fluid, and a manifold adapted for placement at thesubcutaneous tissue site. The manifold includes a plurality of firstconduits, each of the plurality of first conduits having a wall formedwith at least one first aperture and at least one second aperture. Atleast one of the plurality of first conduits is in fluid communicationwith the reduced-pressure source and is operable to deliver the reducedpressure to the subcutaneous tissue site via the at least one firstaperture. The manifold further includes a second conduit formed by aportion of each wall of the plurality of first conduits. The secondconduit is in fluid communication with the plurality of first conduitsvia the at least one second aperture. The system may further include adelivery conduit fluidly coupled to the manifold and reduced-pressuresource.

According to another illustrative, non-limiting embodiment, a manifoldfor applying reduced pressure to a subcutaneous tissue site includes aplurality of first conduits, each of the plurality of first conduitshaving a wall with at least one first aperture and at least one secondaperture. At least one of the plurality of first conduits is operable todeliver reduced pressure to the subcutaneous tissue site via the atleast one first aperture. The plurality of first conduits is coupled ina spaced arrangement that forms an interior space. The manifold furtherincludes a second conduit comprising the interior space and formed by aportion of each wall of the plurality of first conduits. The secondconduit is in fluid communication with the plurality of first conduitsvia the at least one second aperture.

According to another illustrative, non-limiting embodiment, a method forapplying reduced pressure to a subcutaneous tissue site includesproviding a manifold, applying the manifold to the subcutaneous tissuesite, and supplying the reduced pressure to the manifold via a deliveryconduit. The manifold includes a plurality of first conduits. Each ofthe plurality of first conduits has a wall with at least one firstaperture and at least one second aperture. At least one of the pluralityof first conduits is operable to deliver reduced pressure to thesubcutaneous tissue site via the at least one first aperture. Theplurality of first conduits are coupled in a spaced arrangement thatforms an interior space. The manifold further includes a second conduitcomprising the interior space and formed by a portion of each wall ofthe plurality of first conduits. The second conduit is in fluidcommunication with the plurality of first conduits via the at least onesecond aperture.

According to another illustrative, non-limiting embodiment, a method ofmanufacturing an apparatus that is applying reduced pressure to asubcutaneous tissue includes providing a plurality of first conduits.Each of the plurality of first conduits has a wall formed with at leastone first aperture and at least one second aperture. At least one of theplurality of first conduits is operable to deliver reduced pressure tothe subcutaneous tissue site via the at least one first aperture. Themethod further includes coupling the plurality of first conduits to oneanother to form a second conduit. The second conduit is formed by aportion of each wall of the plurality of first conduits and is in fluidcommunication with the plurality of first conduits via the at least onesecond aperture.

According to another illustrative, non-limiting embodiment, a medicalmanifold for delivering one or more fluids to a tissue site includes aplurality of exterior conduits coupled in a spaced relationships todefine an interior space between the plurality of exterior conduits. Theinterior space comprises a central conduit. The medical manifold furtherincludes a plurality of apertures formed on the plurality of externalconduits.

According to another illustrative, non-limiting embodiment, a method ofmanufacturing a medical manifold includes forming four first conduitswith each first conduit touching two other first conduits, forming asecond conduit from the four first conduits, and using a core pin tocreate apertures in the first conduits and the second conduit.

Other features and advantages of the illustrative embodiments willbecome apparent with reference to the drawings and detailed descriptionthat follow.

BRIEF DESCRIPTION OF THE DRAWINGS

The patent or application file contains at least one drawing executed incolor. Copies of this patent or patent application publication withcolor drawing(s) will be provided by the Office upon request and paymentof the necessary fee.

FIG. 1 depicts a perspective view of a reduced-pressure deliveryapparatus according to an embodiment of the present invention, thereduced-pressure delivery apparatus having a plurality of projectionsextending from a flexible barrier to create a plurality of flowchannels;

FIG. 2 illustrates a front view of the reduced-pressure deliveryapparatus of FIG. 1;

FIG. 3 depicts a top view of the reduced-pressure delivery apparatus ofFIG. 1;

FIG. 4A illustrates a side view of the reduced-pressure deliveryapparatus of FIG. 1, the reduced-pressure delivery apparatus having asingle lumen, reduced-pressure delivery tube;

FIG. 4B depicts a side view of an alternative embodiment of thereduced-pressure delivery apparatus of FIG. 1, the reduced-pressuredelivery apparatus having a dual lumen, reduced-pressure delivery tube;

FIG. 5 illustrates an enlarged perspective view of the reduced-pressuredelivery apparatus of FIG. 1;

FIG. 6 depicts a perspective view of a reduced-pressure deliveryapparatus according to an embodiment of the present invention, thereduced-pressure delivery apparatus having a cellular material attachedto a flexible barrier having a spine portion and a pair of wingportions, the cellular material having a plurality of flow channels;

FIG. 7 illustrates a front view of the reduced-pressure deliveryapparatus of FIG. 6;

FIG. 8 depicts a cross-sectional side view of the reduced-pressuredelivery apparatus of FIG. 7 taken at VIII-VIII;

FIG. 8A illustrates a cross-sectional front view of a reduced-pressuredelivery apparatus according to an embodiment of the present invention;

FIG. 8B depicts a side view of the reduced-pressure delivery apparatusof FIG. 8A;

FIG. 9 illustrates a front view of a reduced-pressure delivery apparatusaccording to an embodiment of the present invention being used to applya reduced-pressure tissue treatment to a bone of a patient;

FIG. 10 depicts a front view of a reduced-pressure delivery systemaccording to an embodiment of the present invention, thereduced-pressure delivery system having a manifold delivery tube that isused to percutaneously insert a reduced-pressure delivery apparatus to atissue site;

FIG. 11 illustrates an enlarged front view of the manifold delivery tubeof FIG. 10, the manifold delivery tube containing a reduced-pressuredelivery apparatus having a flexible barrier or a cellular material in acompressed position;

FIG. 12 depicts an enlarged front view of the manifold delivery tube ofFIG. 11, the flexible barrier or cellular material of thereduced-pressure delivery apparatus being shown in an expanded positionafter having been pushed from the manifold delivery tube;

FIG. 13 illustrates a front view of a reduced-pressure delivery systemaccording to an embodiment of the present invention, thereduced-pressure delivery system having a manifold delivery tube that isused to percutaneously insert a reduced-pressure delivery apparatus to atissue site, the reduced-pressure delivery apparatus being shown outsideof the manifold delivery tube but constrained by an impermeable membranein a compressed position;

FIG. 14 depicts a front view of the reduced-pressure delivery system ofFIG. 13, the reduced-pressure delivery apparatus being shown outside ofthe manifold delivery tube but constrained by an impermeable membrane ina relaxed position;

FIG. 15 illustrates a front view of the reduced-pressure delivery systemof FIG. 13, the reduced-pressure delivery apparatus being shown outsideof the manifold delivery tube but constrained by an impermeable membranein an expanded position;

FIG. 15A illustrates a front view of the reduced-pressure deliverysystem of FIG. 13, the reduced-pressure delivery apparatus being shownoutside of the manifold delivery tube but surrounded by an impermeablemembrane in an expanded position;

FIG. 16 depicts a front view of a reduced-pressure delivery systemaccording to an embodiment of the present invention, thereduced-pressure delivery system having a manifold delivery tube that isused to percutaneously insert a reduced-pressure delivery apparatus to atissue site, the reduced-pressure delivery apparatus being shown outsideof the manifold delivery tube but constrained by an impermeable membranehaving a glue seal;

FIG. 16A depicts a front view of a reduced-pressure delivery systemaccording to an embodiment of the present invention;

FIG. 17 illustrates a front view of a reduced-pressure delivery systemaccording to an embodiment of the present invention, thereduced-pressure delivery system having a manifold delivery tube that isused to percutaneously inject a reduced-pressure delivery apparatus to atissue site;

FIG. 17A illustrates a front view of a reduced-pressure delivery systemaccording to an embodiment of the present invention, thereduced-pressure delivery system having a manifold delivery tube that isused to percutaneously deliver a reduced-pressure delivery apparatus toan impermeable membrane positioned at a tissue site;

FIG. 18 depicts a flow chart of a method of administering areduced-pressure tissue treatment to a tissue site according to anembodiment of the present invention;

FIG. 19 illustrates a flow chart of a method of administering areduced-pressure tissue treatment to a tissue site according to anembodiment of the present invention;

FIG. 20 depicts a flow chart of a method of administering areduced-pressure tissue treatment to a tissue site according to anembodiment of the present invention;

FIG. 21 illustrates a flow chart of a method of administering areduced-pressure tissue treatment to a tissue site according to anembodiment of the present invention;

FIG. 22 depicts a cross-sectional front view of a reduced-pressuredelivery apparatus according to an embodiment of the present invention,the reduced-pressure delivery apparatus including a hip prosthesishaving a plurality of flow channels for applying a reduced pressure toan area of bone surrounding the hip prosthesis;

FIG. 23 illustrates a cross-sectional front view of the hip prosthesisof FIG. 22 having a second plurality of flow channels for delivering afluid to the area of bone surrounding the hip prosthesis;

FIG. 24 depicts a flow chart of a method for repairing a joint of apatient using reduced-pressure tissue treatment according to anembodiment of the present invention;

FIG. 25 illustrates a cross-sectional front view of a reduced-pressuredelivery apparatus according to an embodiment of the present invention,the reduced-pressure delivery apparatus including a orthopedic fixationdevice having a plurality of flow channels for applying a reducedpressure to an area of bone adjacent the orthopedic fixation device;

FIG. 26 depicts a cross-sectional front view of the orthopedic fixationdevice of FIG. 25 having a second plurality of flow channels fordelivering a fluid to the area of bone adjacent the orthopedic fixationdevice;

FIG. 27 illustrates a flow chart of a method for healing a bone defectof a bone using reduced-pressure tissue treatment according to anembodiment of the present invention;

FIG. 28 depicts a flow chart of a method of administering areduced-pressure tissue treatment to a tissue site according to anembodiment of the present invention;

FIG. 29 illustrates a flow chart of a method of administering areduced-pressure tissue treatment to a tissue site according to anembodiment of the present invention;

FIGS. 30-38 depict various views of a reduced-pressure delivery systemaccording to an embodiment of the present invention, thereduced-pressure delivery system having a primary manifold that includesa flexible wall surrounding a primary flow passage and a plurality ofapertures in the flexible wall;

FIGS. 39-40 illustrate perspective and top cross-sectional views of areduced-pressure delivery system according to an embodiment of thepresent invention, the reduced-pressure delivery system having a primarymanifold that is integrally connected to a reduced-pressure deliverytube;

FIG. 41 is schematic, perspective view of a manifold according to anillustrative embodiment;

FIG. 42 is a schematic, longitudinal cross-sectional view of themanifold of FIG. 2; and

FIG. 43 is a schematic, lateral cross-sectional view of a manifoldaccording to another illustrative embodiment;

FIG. 44A is a schematic longitudinal cross-sectional view of a manifoldaccording to an illustrative embodiment;

FIG. 44B is a schematic, lateral cross-sectional view of the manifold ofFIG. 44A;

FIG. 45 is a schematic cross-sectional view of a manifold according toan illustrative embodiment;

FIG. 46 is a schematic cross-sectional view of a manifold according toan illustrative embodiment;

FIG. 47 depicts a perspective view of the primary manifolds of FIGS.30-40 being applied with a secondary manifold to a bone tissue site;

FIG. 48 illustrates a schematic view of a reduced-pressure deliverysystem having a valve fluidly connected to a second conduit according toan embodiment of the present invention;

FIG. 49 is a schematic plan view of an apparatus for applying reducedpressure to a subcutaneous tissue site according to an illustrativeembodiment;

FIG. 50 is a schematic side view of an apparatus for applying reducedpressure to a subcutaneous tissue site according to an illustrativeembodiment;

FIG. 51 is a schematic plan view of an apparatus for applying reducedpressure to a subcutaneous tissue site according to an illustrativeembodiment;

FIG. 52 is a schematic perspective view of an apparatus for applyingreduced pressure to a subcutaneous tissue site according to anillustrative embodiment;

FIG. 53 is a schematic cross-sectional view of a manifold according toan illustrative embodiment;

FIG. 54 is a schematic cross-sectional view of a manifold according toan illustrative embodiment;

FIG. 55 is a schematic cross-sectional view of a transition regionaccording to an illustrative embodiment;

FIG. 56 is a schematic cross-sectional view of a delivery tube accordingto an illustrative embodiment;

FIG. 57 is a schematic plan view of an apparatus for applying reducedpressure to a subcutaneous tissue site according to an illustrativeembodiment;

FIG. 58 is a schematic perspective view of an apparatus for applyingreduced pressure to a subcutaneous tissue site according to anillustrative embodiment;

FIG. 59 is a schematic cross-sectional view of a manifold according toan illustrative embodiment;

FIG. 60 is a schematic cross-sectional view of a transition regionaccording to an illustrative embodiment;

FIG. 61 is a schematic cross-sectional view of a delivery tube accordingto an illustrative embodiment;

FIG. 62 is a schematic perspective view of an apparatus for applyingreduced pressure to a subcutaneous tissue site according to anillustrative embodiment;

FIG. 63 is a schematic perspective view of an apparatus for applyingreduced pressure to a subcutaneous tissue site according to anillustrative embodiment;

FIG. 64 is a schematic perspective view of another illustrativeembodiment of a reduced pressure delivery apparatus;

FIG. 65 is a schematic cross sectional view taken along line 65-65 inFIG. 64;

FIG. 66 is a schematic end view of the reduced pressure deliveryapparatus of FIGS. 64 and 65 showing an end cap;

FIG. 67 is a schematic perspective view of another illustrativeembodiment of a reduced pressure delivery apparatus;

FIG. 68 is a schematic, perspective view of a portion of the reducedpressure delivery apparatus of FIG. 67 with a portion broken away toshown an interior portion;

FIG. 69 is a schematic, cross sectional view taken along line 69-69 inFIG. 67; and

FIG. 70 is a schematic, plan view of the reduced pressure deliveryapparatus of FIGS. 67-69.

DETAILED DESCRIPTION

In the following detailed description of the preferred embodiments,reference is made to the accompanying drawings that form a part hereof,and in which is shown by way of illustration specific preferredembodiments in which the invention may be practiced. These embodimentsare described in sufficient detail to enable those skilled in the art topractice the invention, and it is understood that other embodiments maybe utilized and that logical structural, mechanical, electrical, andchemical changes may be made without departing from the spirit or scopeof the invention. To avoid detail not necessary to enable those skilledin the art to practice the invention, the description may omit certaininformation known to those skilled in the art. The following detaileddescription is, therefore, not to be taken in a limiting sense, and thescope of the present invention is defined only by the appended claims.

As used herein, the term “elastomeric” means having the properties of anelastomer. The term “elastomer” refers generally to a polymeric materialthat has rubber-like properties. More specifically, most elastomers havean ultimate elongation greater than 100% and a significant amount ofresilience. The resilience of a material refers to the material'sability to recover from an elastic deformation. Examples of elastomersmay include, but are not limited to, natural rubbers, polyisoprene,styrene butadiene rubber, chloroprene rubber, polybutadiene, nitrilerubber, butyl rubber, ethylene propylene rubber, ethylene propylenediene monomer, chlorosulfonated polyethylene, polysulfide rubber,polyurethane, and silicones.

As used herein, the term “flexible” refers to an object or material thatis able to be bent or flexed. Elastomeric materials are typicallyflexible, but reference to flexible materials herein does notnecessarily limit material selection to only elastomers. The use of theterm “flexible” in connection with a material or reduced-pressuredelivery apparatus of the present invention generally refers to thematerial's ability to conform to or closely match the shape of a tissuesite. For example, the flexible nature of a reduced-pressure deliveryapparatus used to treat a bone defect may allow the apparatus to bewrapped or folded around the portion of the bone having the defect.

The term “fluid” as used herein generally refers to a gas or liquid, butmay also include any other flowable material, including but not limitedto gels, colloids, and foams.

The term “impermeable” as used herein generally refers to the ability ofa membrane, cover, sheet, or other substance to block or slow thetransmission of either liquids or gas. Impermeability may be used torefer to covers, sheets, or other membranes that are resistant to thetransmission of liquids, while allowing gases to transmit through themembrane. While an impermeable membrane may be liquid tight, themembrane may simply reduce the transmission rate of all or only certainliquids. The use of the term “impermeable” is not meant to imply that animpermeable membrane is above or below any particular industry standardmeasurement for impermeability, such as a particular value of watervapor transfer rate (WVTR).

The term “manifold” as used herein generally refers to a substance orstructure that is provided to assist in applying reduced pressure to,delivering fluids to, or removing fluids from a tissue site. A manifoldtypically includes a plurality of flow channels or pathways that areinterconnected to improve distribution of fluids provided to and removedfrom the area of tissue around the manifold. Examples of manifolds mayinclude without limitation devices that have structural elementsarranged to form flow channels, cellular foam, such as open-cell foam,porous tissue collections, and liquids, gels, and foams that include orcure to include flow channels.

The term “reduced pressure” as used herein generally refers to apressure less than the ambient pressure at a tissue site that is beingsubjected to treatment. In most cases, this reduced pressure will beless than the atmospheric pressure at which the patient is located.Alternatively, the reduced pressure may be less than a hydrostaticpressure of tissue at the tissue site. Reduced pressure may initiallygenerate fluid flow in the tube and the area of the tissue site. As thehydrostatic pressure around the tissue site approaches the desiredreduced pressure, the flow may subside, and the reduced pressure is thenmaintained. Unless otherwise indicated, values of pressure stated hereinare gauge pressures.

The term “scaffold” as used herein refers to a substance or structureused to enhance or promote the growth of cells or the formation oftissue. Unless otherwise indicated, “or” does not require mutualexclusivity. A scaffold is typically a three-dimensional porousstructure that provides a template for cell growth. The scaffold may beinfused with, coated with, or comprised of cells, growth factors, orother nutrients to promote cell growth. A scaffold may be used as amanifold in accordance with the embodiments described herein toadminister reduced-pressure tissue treatment to a tissue site.

The term “tissue site” as used herein refers to a wound or defectlocated on or within any tissue, including but not limited to, bonetissue, adipose tissue, muscle tissue, neural tissue, dermal tissue,vascular tissue, connective tissue, cartilage, tendons, or ligaments.The term “tissue site” may further refer to areas of any tissue that arenot necessarily wounded or defective, but are instead areas in which itis desired to add or promote the growth of additional tissue. Forexample, reduced-pressure tissue treatment may be used in certain tissueareas to grow additional tissue that may be harvested and transplantedto another tissue location.

Referring primarily to FIGS. 1-5, a reduced-pressure delivery apparatus,or wing manifold 211 according to the principles of the presentdisclosure includes a flexible barrier 213 having a spine portion 215and a pair of wing portions 219. Each wing portion 219 is positionedalong opposite sides of the spine portion 215. The spine portion 215forms an arcuate channel 223 that may or may not extend the entirelength of the wing manifold 211. Although the spine portion 215 may becentrally located on the wing manifold 211 such that the width of thewing portions 219 is equal, the spine portion 215 may also be offset asillustrated in FIGS. 1-5, resulting in one of the wing portions 219being wider than the other wing portion 219. The extra width of one ofthe wing portions 219 may be particularly useful if the wing manifold211 is being used in connection with bone regeneration or healing andthe wider wing manifold 211 is to be wrapped around fixation hardwareattached to the bone.

The flexible barrier 213 is preferably formed by an elastomeric materialsuch as a silicone polymer. An example of a suitable silicone polymerincludes MED-6015 manufactured by Nusil Technologies of Carpinteria,Calif. It should be noted, however, that the flexible barrier 213 couldbe made from any other biocompatible, flexible material. The flexiblebarrier 213 encases a flexible backing 227 that adds strength anddurability to the flexible barrier 213. The thickness of the flexiblebarrier 213 encasing the flexible backing 227 may be less in the arcuatechannel 223 than that in the wing portions 219. If a silicone polymer isused to form the flexible barrier 213, a silicone adhesive may also beused to aid bonding with the flexible backing 227. An example of asilicone adhesive could include MED-1011, also sold by NusilTechnologies. The flexible backing 227 is preferably made from apolyester knit fabric, such as Bard 6013 manufactured by C.R. Bard ofTempe, Ariz. However, the flexible backing 227 could be made from anybiocompatible, flexible material that is capable of adding strength anddurability to the flexible barrier 213. Under certain circumstances, ifthe flexible barrier 213 is made from a suitably strong material, theflexible backing 227 could be omitted.

It is preferred that either the flexible barrier 213 or the flexiblebacking 227 be impermeable to liquids, air, and other gases, oralternatively, both the flexible backing 227 and the flexible barrier213 may be impermeable to liquids, air, and other gases.

The flexible barrier 213 and flexible backing 227 may also beconstructed from bioresorbable materials that do not have to be removedfrom a patient's body following use of the wing manifold 211. Suitablebioresorbable materials may include, without limitation, a polymericblend of polylactic acid (PLA) and polyglycolic acid (PGA). Thepolymeric blend may also include, without limitation, polycarbonates,polyfumarates, and capralactones. The flexible barrier 213 and theflexible backing 227 may further serve as a scaffold for newcell-growth, or a scaffold material may be used in conjunction with theflexible barrier 213 and flexible backing 227 to promote cell-growth.Suitable scaffold material may include, without limitation, calciumphosphate, collagen, PLA/PGA, coral hydroxy apatites, carbonates, orprocessed allograft materials. Preferably, the scaffold material willhave a high void-fraction (i.e., a high content of air).

In one embodiment the flexible backing 227 may be adhesively attached toa surface of the flexible barrier 213. If a silicone polymer is used toform the flexible barrier 213, a silicone adhesive may also be used toattach the flexible backing 227 to the flexible barrier 213. While anadhesive is the preferred method of attachment when the flexible backing227 is surface bonded to the flexible barrier 213, any suitableattachment may be used.

The flexible barrier 213 includes a plurality of projections 231extending from the wing portions 219 on a surface of the flexiblebarrier 213. The projections 231 may be cylindrical, spherical,hemispherical, cubed, or any other shape, as long as at least someportion of each projection 231 is in a plane different than the planeassociated with the side of the flexible barrier 213 to which theprojections 231 are attached. In this regard, a particular projection231 is not even required to have the same shape or size as otherprojections 231; in fact, the projections 231 may include a random mixof different shapes and sizes. Consequently, the distance by which eachprojection 231 extends from the flexible barrier 213 could vary, but mayalso be uniform among the plurality of projections 231.

The placement of projections 231 on the flexible barrier 213 creates aplurality of flow channels 233 between the projections. When theprojections 231 are of uniform shape and size and are spaced uniformlyon the flexible barrier 213, the flow channels 233 created between theprojections 231 are similarly uniform. Variations in the size, shape,and spacing of the projections 231 may be used to alter the size andflow characteristics of the flow channels 233.

A reduced-pressure delivery tube 241 is positioned within the arcuatechannel 223 and is attached to the flexible barrier 213 as illustratedin FIG. 5. The reduced-pressure delivery tube 241 may be attached solelyto the flexible barrier 213 or the flexible backing 227, or thereduced-pressure delivery tube 241 could be attached to both theflexible barrier 213 and the flexible backing 227. The reduced-pressuredelivery tube 241 includes a distal orifice 243 at a distal end of thereduced-pressure delivery tube 241. The reduced-pressure delivery tube241 may be positioned such that the distal orifice 243 is located at anypoint along the arcuate channel 223, but the reduced-pressure deliverytube 241 is preferably positioned such that the distal orifice 243 islocated approximately midway along the longitudinal length of thearcuate channel 223. The distal orifice 243 is preferably madeelliptical or oval in shape by cutting the reduced-pressure deliverytube 241 along a plane that is oriented less than ninety (90) degrees tothe longitudinal axis of the tube 241. While the distal orifice 243 mayalso be round, the elliptical shape of the distal orifice 243 increasesfluid communication with the flow channels 233 formed between theprojections 231.

The reduced-pressure delivery tube 241 is preferably made fromparalyne-coated silicone or urethane. However, any medical-grade tubingmaterial may be used to construct the reduced-pressure delivery tube241. Other coatings that may coat the tube include heparin,anti-coagulants, anti-fibrinogens, anti-adherents, anti-thrombinogens,and hydrophilic coatings.

In one embodiment, the reduced-pressure delivery tube 241 may alsoinclude vent openings, or vent orifices 251 positioned along thereduced-pressure delivery tube 241 as either an alternative to thedistal orifice 243 or in addition to the distal orifice 243 to furtherincrease fluid communication between the reduced-pressure delivery tube241 and the flow channels 233. The reduced-pressure delivery tube 241may be positioned along only a portion of the longitudinal length of thearcuate channel 223 as shown in FIGS. 1-5, or alternatively may bepositioned along the entire longitudinal length of the arcuate channel223. If positioned such that the reduced-pressure delivery tube 241occupies the entire length of the arcuate channel 223, the distalorifice 243 may be capped such that all fluid communication between thetube 241 and the flow channels 233 occurs through the vent orifices 251.

The reduced-pressure delivery tube 241 further includes a proximalorifice 255 at a proximal end of the tube 241. The proximal orifice 255is configured to mate with a reduced-pressure source, which is describedin more detail below with reference to FIG. 9. The reduced-pressuredelivery tube 241 illustrated in FIGS. 1-3, 4A, and 5 includes only asingle lumen, or passageway 259. It is possible, however, for thereduced-pressure delivery tube 241 to include multiple lumens, such as adual lumen tube 261 illustrated in FIG. 4B. The dual lumen tube 261includes a first lumen 263 and a second lumen 265. The use of a duallumen tube provides separate paths of fluid communication between theproximal end of the reduced-pressure delivery tube 241 and the flowchannels 233. For example, the use of the dual lumen tube 261 may beused to allow communication between the reduced-pressure source and theflow channels 233 along the first lumen 263. The second lumen 265 may beused to introduce a fluid to the flow channels 233. The fluid may befiltered air or other gases, antibacterial agents, antiviral agents,cell-growth promotion agents, irrigation fluids, chemically activefluids, or any other fluid. If it is desired to introduce multiplefluids to the flow channels 233 through separate fluid communicationpaths, a reduced-pressure delivery tube may be provided with more thantwo lumens.

Referring still to FIG. 4B, a horizontal divider 271 separates the firstand second lumens 263, 265 of the reduced-pressure delivery tube 241,resulting in the first lumen 263 being positioned above the second lumen265. The relative position of the first and second lumens 263, 265 mayvary, depending on how fluid communication is provided between the firstand second lumens 263, 265 and the flow channels 233. For example, whenthe first lumen 263 is positioned as illustrated in FIG. 4B, ventopenings similar to vent openings 251 may be provided to allowcommunication with the flow channels 233. When the second lumen 265 ispositioned as illustrated in FIG. 4B, the second lumen 265 maycommunicate with the flow channels 233 through a distal orifice similarto distal orifice 243. Alternatively, the multiple lumens of areduced-pressure delivery tube could be positioned side by side with avertical divider separating the lumens, or the lumens could be arrangedconcentrically or coaxially.

It should be apparent to a person having ordinary skill in the art thatthe provision of independent paths of fluid communication could beaccomplished in a number of different ways, including that of providinga multi-lumen tube as described above. Alternatively, independent pathsof fluid communication may be provided by attaching a single lumen tubeto another single lumen tube, or by using separate, unattached tubeswith single or multiple lumens.

If separate tubes are used to provide separate paths of fluidcommunication to the flow channels 233, the spine portion 215 mayinclude multiple arcuate channels 223, one for each tube. Alternativelythe arcuate channel 223 may be enlarged to accommodate multiple tubes.An example of a reduced-pressure delivery apparatus having areduced-pressure delivery tube separate from a fluid delivery tube isdiscussed in more detail below with reference to FIG. 9.

Referring primarily to FIGS. 6-8, a reduced-pressure delivery apparatus,or wing manifold 311 according to the principles of the presentdisclosure includes a flexible barrier 313 having a spine portion 315and a pair of wing portions 319. Each wing portion 319 is positionedalong opposite sides of the spine portion 315. The spine portion 315forms an arcuate channel 323 that may or may not extend the entirelength of the wing manifold 311. Although the spine portion 315 may becentrally located on the wing manifold 311 such that the size of thewing portions 319 is equal, the spine portion 315 may also be offset asillustrated in FIGS. 6-8, resulting in one of the wing portions 319being wider than the other wing portion 319. The extra width of one ofthe wing portions 319 may be particularly useful if the wing manifold311 is being used in connection with bone regeneration or healing andthe wider wing manifold 311 is to be wrapped around fixation hardwareattached to the bone.

A cellular material 327 is attached to the flexible barrier 313 and maybe provided as a single piece of material that covers the entire surfaceof the flexible barrier 313, extending across the spine portion 315 andboth wing portions 319. The cellular material 327 includes an attachmentsurface (not visible in FIG. 6) that is disposed adjacent to theflexible barrier 313, a main distribution surface 329 opposite theattachment surface, and a plurality of perimeter surfaces 330.

In one embodiment the flexible barrier 313 may be similar to flexiblebarrier 213 and include a flexible backing. While an adhesive is apreferred method of attaching the cellular material 327 to the flexiblebarrier 313, the flexible barrier 313 and cellular material 327 could beattached by any other suitable attachment method or left for the user toassemble at the site of treatment. The flexible barrier 313 or flexiblebacking serve as an impermeable barrier to transmission of fluids, suchas liquids, air, and other gases.

In one embodiment, a flexible barrier and flexible backing may not beseparately provided to back the cellular material 327. Rather, thecellular material 327 may have an integral barrier layer that is animpermeable portion of the cellular material 327. The barrier layercould be formed from closed-cell material to prevent transmission offluids, thereby substituting for the flexible barrier 313. If anintegral barrier layer is used with the cellular material 327, thebarrier layer may include a spine portion and wing portions as describedpreviously with reference to the flexible barrier 313.

The flexible barrier 313 is preferably made from an elastomericmaterial, such as a silicone polymer. An example of a suitable siliconepolymer includes MED-6015 manufactured by Nusil Technologies ofCarpinteria, Calif. It should be noted, however, that the flexiblebarrier 313 could be made from any other biocompatible, flexiblematerial. If the flexible barrier encases or otherwise incorporates aflexible backing, the flexible backing is preferably made from apolyester knit fabric such as Bard 6013 manufactured by C.R. Bard ofTempe, Ariz. However, the flexible backing could be made from anybiocompatible, flexible material that is capable of adding strength anddurability to the flexible barrier 313.

In one embodiment, the cellular material 327 is an open-cell,reticulated polyetherurethane foam with pore sizes ranging from about400-600 microns. An example of this foam may include GranuFoam® materialmanufactured by Kinetic Concepts, Inc. of San Antonio, Tex. The cellularmaterial 327 may also be gauze, felted mats, or any other biocompatiblematerial that provides fluid communication through a plurality ofchannels in three dimensions.

The cellular material 327 is primarily an “open cell” material thatincludes a plurality of cells fluidly connected to adjacent cells. Aplurality of flow channels is formed by and between the “open cells” ofthe cellular material 327. The flow channels allow fluid communicationthroughout that portion of the cellular material 327 having open cells.The cells and flow channels may be uniform in shape and size, or mayinclude patterned or random variations in shape and size. Variations inshape and size of the cells of the cellular material 327 result invariations in the flow channels, and such characteristics can be used toalter the flow characteristics of fluid through the cellular material327. The cellular material 327 may further include portions that include“closed cells.” These closed-cell portions of the cellular material 327contain a plurality of cells, the majority of which are not fluidlyconnected to adjacent cells. An example of a closed-cell portion isdescribed above as a barrier layer that may be substituted for theflexible barrier 313. Similarly, closed-cell portions could beselectively disposed in the cellular material 327 to preventtransmission of fluids through the perimeter surfaces 330 of thecellular material 327.

The flexible barrier 313 and cellular material 327 may also beconstructed from bioresorbable materials that do not have to be removedfrom a patient's body following use of the reduced-pressure deliveryapparatus 311. Suitable bioresorbable materials may include, withoutlimitation, a polymeric blend of polylactic acid (PLA) and polyglycolicacid (PGA). The polymeric blend may also include without limitationpolycarbonates, polyfumarates, and capralactones. The flexible barrier313 and the cellular material 327 may further serve as a scaffold fornew cell-growth, or a scaffold material may be used in conjunction withthe flexible barrier 313, flexible backing, or cellular material 327 topromote cell-growth. Suitable scaffold materials may include, withoutlimitation, calcium phosphate, collagen, PLA/PGA, coral hydroxyapatites, carbonates, or processed allograft materials. Preferably, thescaffold material will have a high void-fraction (i.e. a high content ofair).

A reduced-pressure delivery tube 341 is positioned within the arcuatechannel 323 and is attached to the flexible barrier 313. Thereduced-pressure delivery tube 341 may also be attached to the cellularmaterial 327, or in the case of only a cellular material 327 beingpresent, the reduced-pressure delivery tube 341 may be attached to onlythe cellular material 327. The reduced-pressure delivery tube 341includes a distal orifice 343 at a distal end of the reduced-pressuredelivery tube 341 similar to the distal orifice 243 of FIG. 5. Thereduced-pressure delivery tube 341 may be positioned such that thedistal orifice 343 is located at any point along the arcuate channel323, but is preferably located approximately midway along thelongitudinal length of the arcuate channel 323. The distal orifice 343is preferably made elliptical or oval in shape by cutting thereduced-pressure delivery tube 341 along a plane that is oriented lessthan ninety (90) degrees to the longitudinal axis of thereduced-pressure delivery tube 341. While the orifice may also be round,the elliptical shape of the orifice increases fluid communication withthe flow channels in the cellular material 327.

In one embodiment, the reduced-pressure delivery tube 341 may alsoinclude vent openings, or vent orifices (not shown) similar to ventopenings 251 of FIG. 5. The vent openings are positioned along thereduced-pressure delivery tube 341 as either an alternative to thedistal orifice 343 or in addition to the distal orifice 343 to furtherincrease fluid communication between the reduced-pressure delivery tube341 and the flow channels. As previously described, the reduced-pressuredelivery tube 341 may be positioned along only a portion of thelongitudinal length of the arcuate channel 323, or alternatively may bepositioned along the entire longitudinal length of the arcuate channel323. If positioned such that the reduced-pressure delivery tube 341occupies the entire arcuate channel 323, the distal orifice 343 may becapped such that all fluid communication between the reduced-pressuredelivery tube 341 and the flow channels occurs through the ventopenings.

Preferably, the cellular material 327 overlays and directly contacts thereduced-pressure delivery tube 341. The cellular material 327 may beconnected to the reduced-pressure delivery tube 341, or the cellularmaterial 327 may simply be attached to the flexible barrier 313. If thereduced-pressure delivery tube 341 is positioned such that it onlyextends to a midpoint of the arcuate channel 323, the cellular material327 may also be connected to the spine portion 315 of the flexiblebarrier 313 in that area of the arcuate channel 323 that does notcontain the reduced-pressure delivery tube 341.

The reduced-pressure delivery tube 341 further includes a proximalorifice 355 at a proximal end of the reduced-pressure delivery tube 341.The proximal orifice 355 is configured to mate with a reduced-pressuresource, which is described in more detail below with reference to FIG.9. The reduced-pressure delivery tube 341 illustrated in FIGS. 6-8includes only a single lumen, or passageway 359. It is possible,however, for the reduced-pressure delivery tube 341 to include multiplelumens such as those described previously with reference to FIG. 4B. Theuse of a multiple lumen tube provides separate paths of fluidcommunication between the proximal end of the reduced-pressure deliverytube 341 and the flow channels as previously described. These separatepaths of fluid communication may also be provided by separate tubeshaving single or multiple lumens that communicate with the flowchannels.

Referring primarily to FIGS. 8A and 8B, a reduced-pressure deliveryapparatus 371 according to the principles of the present disclosureincludes a reduced-pressure delivery tube 373 having an extensionportion 375 at a distal end 377 of the reduced-pressure delivery tube373. The extension portion 375 is preferably arcuately shaped to matchthe curvature of the reduced-pressure delivery tube 373. The extensionportion 375 may be formed by removing a portion of the reduced-pressuredelivery tube 373 at the distal end 377, thereby forming a cut-out 381having a shoulder 383. A plurality of projections 385 is disposed on aninner surface 387 of the reduced-pressure delivery tube 373 to form aplurality of flow channels 391 between the projections 385. Theprojections 385 may be similar in size, shape, and spacing as theprojections described with reference to FIGS. 1-5. The reduced-pressuredelivery apparatus 371 is particularly suited for applying reducedpressure to and regenerating tissue on connective tissues that arecapable of being received within the cut-out 381. Ligaments, tendons,and cartilage are non-limiting examples of the tissues that may betreated by reduced-pressure delivery apparatus 371.

Referring primarily to FIG. 9, a reduced-pressure delivery apparatus 411similar to the other reduced-pressure delivery apparatuses describedherein is used to apply a reduced-pressure tissue treatment to a tissuesite 413, such as a human bone 415 of a patient. When used to promotebone tissue growth, reduced-pressure tissue treatment can increase therate of healing associated with a fracture, a non-union, a void, orother bone defects. It is further believed that reduced-pressure tissuetreatment may be used to improve recovery from osteomyelitis. Thetherapy may further be used to increase localized bone densities inpatients suffering from osteoporosis. Finally, reduced-pressure tissuetreatment may be used to speed and improve oseointegration of orthopedicimplants such as hip implants, knee implants, and fixation devices.

Referring still to FIG. 9, the reduced-pressure delivery apparatus 411includes a reduced-pressure delivery tube 419 having a proximal end 421fluidly connected to a reduced-pressure source 427. The reduced-pressuresource 427 is a pump or any other device that is capable of applying areduced pressure to the tissue site 413 through the reduced-pressuredelivery tube 419 and a plurality of flow channels associated with thereduced-pressure delivery apparatus 411. Applying reduced pressure tothe tissue site 413 is accomplished by placing the wing portions of thereduced-pressure delivery apparatus 411 adjacent the tissue site 413,which in this particular example involves wrapping the wing portionsaround a void defect 429 in the bone 415. The reduced-pressure deliveryapparatus 411 may be surgically or percutaneously inserted. Whenpercutaneously inserted, the reduced-pressure delivery tube 419 ispreferably inserted through a sterile insertion sheath that penetratesthe skin tissue of the patient.

The application of reduced-pressure tissue treatment typically generatesgranulation tissue in the area surrounding the tissue site 413.Granulation tissue is a common tissue that often forms prior to tissuerepair in the body. Under normal circumstances, granulation tissue mayform in response to a foreign body or during wound healing. Granulationtissue typically serves as a scaffold for healthy replacement tissue andfurther results in the development of some scar tissue. Granulationtissue is highly vascularized, and the increased growth and growth rateof the highly vascularized tissue in the presence of reduced pressurepromotes new tissue growth at the tissue site 413.

Referring still to FIG. 9, a fluid delivery tube 431 may be fluidlyconnected at a distal end to the flow channels of the reduced-pressuredelivery apparatus 411. The fluid delivery tube 431 includes a proximalend 432 that is fluidly connected to a fluid delivery source 433. If thefluid being delivered to the tissue site is air, the air is preferablyfiltered by a filter 434 capable of filtering particles at least assmall as 0.22 μm in order to clean and sterilize the air. Theintroduction of air to the tissue site 413, especially when the tissuesite 413 is located beneath the surface of the skin, is important tofacilitate good drainage of the tissue site 413, thereby reducing orpreventing obstruction of the reduced-pressure delivery tube 419. Thefluid delivery tube 431 and fluid delivery source 433 could also be usedto introduce other fluids to the tissue site 413, including withoutlimitation an antibacterial agent, an antiviral agent, a cell-growthpromotion agent, an irrigation fluid, or other chemically active agents.When percutaneously inserted, the fluid delivery tube 431 is preferablyinserted through a sterile insertion sheath that penetrates the skintissue of the patient.

A pressure sensor 435 may be operably connected to the fluid deliverytube 431 to indicate whether the fluid delivery tube 431 is occludedwith blood or other bodily fluids. The pressure sensor 435 may beoperably connected to the fluid delivery source 433 to provide feedbackso that the amount of fluid introduced to the tissue site 413 iscontrolled. A check valve (not shown) may also be operably connectednear the distal end of the fluid delivery tube 431 to prevent blood orother bodily fluids from entering the fluid delivery tube 431.

The independent paths of fluid communication provided byreduced-pressure delivery tube 419 and fluid delivery tube 431 may beaccomplished in a number of different ways, including that of providinga single, multi-lumen tube as described previously with reference toFIG. 4B. A person of ordinary skill in the art will recognize that thesensors, valves, and other components associated with the fluid deliverytube 431 could also be similarly associated with a particular lumen inthe reduced-pressure delivery tube 419 if a multi-lumen tube is used. Itis preferred that any lumen or tube that fluidly communicates with thetissue site be coated with an anti-coagulant to prevent a build-up ofbodily fluids or blood within the lumen or tube. Other coatings that maycoat the lumens or tubes include without limitation heparin,anti-coagulants, anti-fibrinogens, anti-adherents, anti-thrombinogens,and hydrophilic coatings.

Referring primarily to FIG. 10, a reduced-pressure delivery system 711according to an embodiment of the present disclosure deliversreduced-pressure tissue treatment to a tissue site 713 of a patient. Thereduced-pressure delivery system 711 includes a manifold delivery tube721. The manifold delivery tube 721 may be a catheter or cannula and mayinclude features, such as a steering unit 725 and a guide wire 727 thatallow the manifold delivery tube 721 to be guided to the tissue site713. Placement and direction of the guide wire 727 and the manifolddelivery tube 721 may be accomplished by using endoscopy, ultrasound,fluoroscopy, auscultation, palpation, or any other suitable localizationtechnique. The manifold delivery tube 721 is provided to percutaneouslyinsert a reduced-pressure delivery apparatus to the tissue site 713 ofthe patient. When percutaneously inserted, the manifold delivery tube721 is preferably inserted through a sterile insertion sheath thatpenetrates the skin tissue of the patient.

In FIG. 10, the tissue site 713 includes bone tissue adjacent a fracture731 on a bone 733 of the patient. The manifold delivery tube 721 isinserted through the patient's skin 735 and any soft tissue 739surrounding the bone 733. As previously discussed, the tissue site 713may also include any other type of tissue, including, withoutlimitation, adipose tissue, muscle tissue, neural tissue, dermal tissue,vascular tissue, connective tissue, cartilage, tendons, or ligaments.

Referring primarily to FIGS. 11 and 12, the reduced-pressure deliverysystem 711 is further illustrated. The manifold delivery tube 721 mayinclude a tapered distal end 743 to ease insertion through the patient'sskin 735 and soft tissue 739 in FIG. 10. The tapered distal end 743 mayfurther be configured to flex radially outward to an open position suchthat the inner diameter of the tapered distal end 743 would besubstantially the same as or greater than the inner diameter at otherportions of the tube 721. The open position of the tapered distal end743 is schematically illustrated in FIG. 11 by broken lines 737.

The manifold delivery tube 721 further includes a passageway 751 inwhich a reduced-pressure delivery apparatus 761, or any otherreduced-pressure delivery apparatus, is contained. The reduced-pressuredelivery apparatus 761 includes a flexible barrier 765 or cellularmaterial 767 similar to that described with reference to FIGS. 6-8. Theflexible barrier 765 or cellular material 767 is preferably rolled,folded, or otherwise compressed around a reduced-pressure delivery tube769 to reduce the cross-sectional area of the reduced-pressure deliveryapparatus 761 within the passageway 751.

The reduced-pressure delivery apparatus 761 may be placed within thepassageway 751 and guided to the tissue site 713 following the placementof the tapered distal end 743 manifold delivery tube 721 at the tissuesite 713. Alternatively, the reduced-pressure delivery apparatus 761 maybe pre-positioned within the passageway 751 prior to the manifolddelivery tube 721 being inserted into the patient. If thereduced-pressure delivery apparatus 761 is to be pushed through thepassageway 751, a biocompatible lubricant may be used to reduce frictionbetween the reduced-pressure delivery apparatus 761 and the manifolddelivery tube 721. When the tapered distal end 743 has been positionedat the tissue site 713 and the reduced-pressure delivery apparatus 761has been delivered to the tapered distal end 743, the reduced-pressuredelivery apparatus 761 is then pushed toward the tapered distal end 743,causing the tapered distal end 743 to expand radially outward into theopen position. The reduced-pressure delivery apparatus 761 is pushed outof the manifold delivery tube 721, preferably into a void or spaceadjacent the tissue site 713. The void or space is typically formed bydissection of soft tissue, which may be accomplished by percutaneousmeans. In some cases, the tissue site 713 may be located at a woundsite, and a void may be naturally present due to the anatomy of thewound. In other instances, the void may be created by balloondissection, sharp dissection, blunt dissection, hydrodissection,pneumatic dissection, ultrasonic dissection, electrocautery dissection,laser dissection, or any other suitable dissection technique. When thereduced-pressure delivery apparatus 761 enters the void adjacent thetissue site 713, the flexible barrier 765 or cellular material 767 ofthe reduced-pressure delivery apparatus 761 either unrolls, unfolds, ordecompresses (see FIG. 12) such that the reduced-pressure deliveryapparatus 761 can be placed in contact with the tissue site 713.Although not required, the flexible barrier 765 or cellular material 767may be subjected to a vacuum or reduced pressure supplied through thereduced-pressure delivery tube 769 to compress the flexible barrier 765or cellular material 767. The unfolding of the flexible barrier 765 orcellular material 767 may be accomplished by either relaxing the reducedpressure supplied through the reduced-pressure delivery tube 769 or bysupplying a positive pressure through the reduced-pressure delivery tube769 to assist the unrolling process. Final placement and manipulation ofthe reduced-pressure delivery apparatus 761 may be accomplished by usingendoscopy, ultrasound, fluoroscopy, auscultation, palpation, or anyother suitable localization technique. Following placement of thereduced-pressure delivery apparatus 761, the manifold delivery tube 721is preferably removed from the patient, but the reduced-pressuredelivery tube associated with reduced-pressure delivery apparatus 761remains in situ to allow percutaneous application of reduced pressure tothe tissue site 713.

Referring primarily to FIGS. 13-15, a reduced-pressure delivery system811 according to an embodiment of the present disclosure includes amanifold delivery tube 821 having a tapered distal end 843 that isconfigured to flex radially outward to an open position such that theinner diameter of the distal end 843 would be substantially the same asor greater than the inner diameter at other portions of the manifolddelivery tube 821. The open position of the distal end 843 isschematically illustrated in FIGS. 13-15 by broken lines 837.

The manifold delivery tube 821 further includes a passageway in which areduced-pressure delivery apparatus 861 similar to the otherreduced-pressure delivery apparatuses described herein is contained. Thereduced-pressure delivery apparatus 861 includes a flexible barrier 865or a cellular material 867 that is preferably rolled, folded, orotherwise compressed around a reduced-pressure delivery tube 869 toreduce the cross-sectional area of the reduced-pressure deliveryapparatus 861 within the passageway.

An impermeable membrane 871 having an inner space 873 is disposed aroundthe reduced-pressure delivery apparatus 861 such that thereduced-pressure delivery apparatus 861 is contained within the innerspace 873 of the impermeable membrane 871. The impermeable membrane 871may be a balloon, a sheath, or any other type of membrane that iscapable of preventing fluid transmission such that the impermeablemembrane 871 can assume at least one of a compressed position (see FIG.13), a relaxed position (see FIG. 14), and an expanded position (seeFIGS. 15 and 15A). The impermeable membrane 871 may be sealinglyconnected to the manifold delivery tube 821 such that the inner space873 of the impermeable membrane 871 is in fluid communication with thepassageway of the manifold delivery tube 821. The impermeable membrane871 may alternatively be attached to the reduced-pressure delivery tube869 such that the inner space 873 of the impermeable membrane 871 is influid communication with the passageway of the reduced-pressure deliverytube 869. The impermeable membrane 871 instead may be attached to aseparate control tube or control lumen (see for example FIG. 15A) thatfluidly communicates with the inner space 873.

In one embodiment, the impermeable membrane 871 may be provided tofurther reduce the cross-sectional area of the reduced-pressure deliveryapparatus 861 within the passageway. To accomplish this, a pressure isapplied to the inner space 873 of the impermeable membrane 871 that isless than the ambient pressure surrounding the impermeable membrane 871.A significant portion of the air or other fluid within the inner space873 is thereby evacuated, placing the impermeable membrane 871 in thecompressed position illustrated in FIG. 13. In the compressed position,the impermeable membrane 871 is drawn inward such that a compressiveforce is applied to the reduced-pressure delivery apparatus 861 tofurther reduce the cross-sectional area of the reduced-pressure deliveryapparatus 861. As previously described with reference to FIGS. 11 and12, the reduced-pressure delivery apparatus 861 may be delivered to thetissue site following the placement of the distal end 843 of themanifold delivery tube 821 at the tissue site. Placement andmanipulation of the impermeable membrane 871 and the reduced-pressuredelivery apparatus 861 may be accomplished by using endoscopy,ultrasound, fluoroscopy, auscultation, palpation, or any other suitablelocalization technique. The impermeable membrane 871 may includeradio-opaque markers 881 that improve visualization of the impermeablemembrane 871 under fluoroscopy prior to its removal.

After pushing the reduced-pressure delivery apparatus 861 through thedistal end 843, the reduced pressure applied to the inner space 873 maybe eased to place the impermeable membrane 871 in the relaxed position(see FIG. 14), thereby facilitating easier removal of thereduced-pressure delivery apparatus 861 from the impermeable membrane871. A removal instrument 885, such as a trocar, stylet, or other sharpinstrument may be provided to rupture the impermeable membrane 871.Preferably, the removal instrument 885 is inserted through thereduced-pressure delivery tube 869 and is capable of being advanced intocontact with the impermeable membrane 871. After rupture of theimpermeable membrane 871, the removal instrument 885 and the impermeablemembrane 871 may be withdrawn through the manifold delivery tube 821,allowing the flexible barrier 865 or cellular material 867 of thereduced-pressure delivery apparatus 861 to unroll, unfold, or decompresssuch that the reduced-pressure delivery apparatus 861 can be placed incontact with the tissue site. The unrolling of the flexible barrier 865or cellular material 867 may occur automatically following therelaxation of reduced pressure to the inner space 873 and the removal ofthe impermeable membrane 871. In some cases, a positive pressure may bedelivered through the reduced-pressure delivery tube 869 to assist inunrolling or decompressing the flexible barrier 865 or cellular material867. Following final placement of the reduced-pressure deliveryapparatus 861, the manifold delivery tube 821 is preferably removed fromthe patient, but the reduced-pressure delivery tube 869 associated withthe reduced-pressure delivery apparatus 861 remains in situ to allowpercutaneous application of reduced pressure to the tissue site.

The impermeable membrane 871 may also be used to dissect tissue adjacentthe tissue site prior to placing the reduced-pressure delivery apparatus861 against the tissue site. After pushing the reduced-pressure deliveryapparatus 861 and intact impermeable membrane 871 through the distal end843 of the manifold delivery tube 821, air or another fluid may beinjected or pumped into the inner space 873 of the impermeable membrane871. A liquid is preferably used to inflate the impermeable membrane 871since the incompressibility of liquids allow the impermeable membrane871 to expand more evenly and consistently. The impermeable membrane 871may expand radially as illustrated in FIG. 15 or directionally dependingon its method of manufacture and attachment to the manifold deliverytube 821. As the impermeable membrane 871 expands outward into theexpanded position (see FIG. 15) due to the pressure of the air or fluid,a void is dissected adjacent the tissue site. When the void is largeenough, the liquid, air or other fluid may be released from the innerspace 873 to allow the impermeable membrane 871 to assume the relaxedposition. The impermeable membrane 871 may then be ruptured aspreviously explained and the reduced-pressure delivery apparatus 861inserted adjacent the tissue site.

Referring primarily to FIG. 15A, if the impermeable membrane 871 is usedprimarily to dissect tissue adjacent the tissue site, the impermeablemembrane 871 may be sealingly attached to the manifold delivery tube 821such that the inner space 873 fluidly communicates with a secondarylumen, or tube 891, associated with or attached to the manifold deliverytube 821. The secondary lumen 891 may be used to deliver a liquid, air,or other fluid to the inner space 873 to place the impermeable membrane871 in the expanded position. Following dissection, the impermeablemembrane 871 may be relaxed and ruptured as previously described withreference to FIG. 14.

Referring primarily to FIG. 16, a reduced-pressure delivery system 911according to an embodiment of the present disclosure includes a manifolddelivery tube 921 having a tapered distal end 943 that is configured toflex radially outward to an open position such that the inner diameterof the distal end 943 would be substantially the same as or greater thanthe inner diameter at other portions of the manifold delivery tube 921.The open position of the distal end 943 is schematically illustrated inFIG. 16 by broken lines 937.

The manifold delivery tube 921 further includes a passageway in which areduced-pressure delivery apparatus 961 similar to the otherreduced-pressure delivery apparatuses described herein is contained. Thereduced-pressure delivery apparatus 961 includes a flexible barrier 965or a cellular material 967 that is preferably rolled, folded, orotherwise compressed around a reduced-pressure delivery tube 969 toreduce the cross-sectional area of the reduced-pressure deliveryapparatus 961 within the passageway of the manifold delivery tube 921.

An impermeable membrane 971 having an inner space 973 is disposed aroundthe reduced-pressure delivery apparatus 961 such that thereduced-pressure delivery apparatus 961 is contained within the innerspace 973 of the impermeable membrane 971. The impermeable membrane 971includes a glue seal 977 on one end of the impermeable membrane 971 toprovide an alternative method of removing the reduced-pressure deliveryapparatus 961 from the impermeable membrane 971. The impermeablemembrane 971 may be sealingly connected at another end to the manifolddelivery tube 921 such that the inner space 973 of the impermeablemembrane 971 is in fluid communication with the passageway of themanifold delivery tube 921. Alternatively, the impermeable membrane 971may be attached to a separate control tube (not shown) that fluidlycommunicates with the inner space 973.

Similar to the impermeable membrane 871 of FIG. 13, impermeable membrane971 may be capable of preventing fluid transmission such that theimpermeable membrane 971 can assume at least one of a compressedposition, a relaxed position, and an expanded position. Since theprocedures for placing the impermeable membrane 971 in a compressedposition and an expanded position are similar to those for impermeablemembrane 871, only the differing process of removing thereduced-pressure delivery apparatus 961 is described.

The reduced-pressure delivery apparatus 961 is delivered to the tissuesite within the impermeable membrane 971 and then properly positionedusing endoscopy, ultrasound, fluoroscopy, auscultation, palpation, orany other suitable localization technique. The impermeable membrane 971may include radio-opaque markers 981 that improve visualization of theimpermeable membrane 971 under fluoroscopy prior to its removal. Thereduced-pressure delivery apparatus 961 is then pushed through thedistal end 943 of the manifold delivery tube 921. The reduced pressureapplied to the inner space 973 may be eased to place the impermeablemembrane 971 in the relaxed position. The reduced-pressure deliveryapparatus 961 is then pushed through the glue seal 977 to exit theimpermeable membrane 971.

Referring primarily to FIG. 16A, a reduced-pressure delivery system 985according to an embodiment of the present disclosure may not include amanifold delivery tube similar to manifold delivery tube 921 of FIG. 16.Instead, the reduced-pressure delivery system 985 may include a guidewire 987, a reduced-pressure delivery tube 989, and a reduced-pressuredelivery apparatus 991. The reduced-pressure delivery apparatus 991includes a plurality flow channels that is fluidly connected to thereduced-pressure delivery tube 989. Instead of using an independentmanifold delivery tube to deliver the reduced-pressure deliveryapparatus 991, the reduced-pressure delivery apparatus 991 andreduced-pressure delivery tube 989 are placed on the guide wire 987,which is percutaneously guided to a tissue site 993. Preferably, theguide wire 987 and reduced-pressure delivery tube 989 penetrate the skinof the patient through a sterile sheath. By guiding the reduced-pressuredelivery tube 989 and reduced-pressure delivery apparatus 991 along theguide wire 987, the reduced-pressure delivery apparatus 991 may beplaced at the tissue site 993 to allow percutaneous application ofreduced-pressure tissue treatment.

Since the reduced-pressure delivery apparatus 991 is not constrainedwithin a manifold delivery tube during delivery to the tissue site 993,it is preferable to hold the reduced-pressure delivery apparatus 991 ina compressed position during delivery. If an elastic foam is used as thereduced-pressure delivery apparatus 991, a biocompatible, solubleadhesive may be applied to the foam and the foam compressed. Uponarrival at the tissue site, bodily fluids or other fluids deliveredthrough the reduced-pressure delivery tube 989 dissolve the adhesive,allowing the foam to expand into contact with the tissue site.Alternatively, the reduced-pressure delivery apparatus 991 may be formedfrom a compressed, dry hydrogel. The hydrogel absorbs moisture followingdelivery to the tissue site 993 allowing expansion of thereduced-pressure delivery apparatus 991. Still another reduced-pressuredelivery apparatus 991 may be made from a thermoactive material (e.g.,polyethylene glycol) that expands at the tissue site 993 when exposed tothe body heat of the patient. In still another embodiment, a compressedreduced-pressure delivery apparatus 991 may be delivered to the tissuesite 993 in a dissolvable membrane.

Referring primarily to FIG. 17, a reduced-pressure delivery system 1011according to an embodiment of the present disclosure includes a manifolddelivery tube 1021 having a distal end 1043 that is inserted through atissue of a patient to access a tissue site 1025. The tissue site 1025may include a void 1029 that is associated with a wound or other defect,or alternatively a void may be created by dissection, including thedissection techniques described herein.

Following placement of the distal end 1043 within the void 1029 adjacentthe tissue site 1025, an injectable, pourable, or flowablereduced-pressure delivery apparatus 1035 is delivered through themanifold delivery tube 1021 to the tissue site 1025. Thereduced-pressure delivery apparatus 1035 preferably exists in a flowablestate during delivery to the tissue site, and then, after arrival formsa plurality of flow channels for distribution of reduced pressure orfluids. In some cases, the flowable material may harden into a solidstate after arrival at the tissue site, either through a drying process,a curing process, or other chemical or physical reaction. In othercases, the flowable material may form a foam in situ following deliveryto the tissue site. Still other materials may exist in a gel-like stateat the tissue site 1025 but still have a plurality of flow channels fordelivering reduced pressure. The amount of reduced-pressure deliveryapparatus 1035 delivered to the tissue site 1025 may be enough topartially or completely fill the void 1029. The reduced-pressuredelivery apparatus 1035 may include aspects of both a manifold and ascaffold. As a manifold, the reduced-pressure delivery apparatus 1035includes a plurality of pores or open cells that may be formed in thematerial after delivery to the void 1029. The pores or open cellscommunicate with one another, thereby creating a plurality of flowchannels. The flow channels are used to apply and distribute reducedpressure to the tissue site 1025. As a scaffold, the reduced-pressuredelivery apparatus 1035 is bioresorbable and serves as a substrate uponand within which new tissue may grow.

In one embodiment, the reduced-pressure delivery apparatus 1035 mayinclude poragens, such as NaCl or other salts that are distributedthroughout a liquid or viscous gel. After the liquid or viscous gel isdelivered to the tissue site 1025, the material conforms to the void1029 and then cures into a solid mass. The water-soluble NaCl poragensdissolve in the presence of bodily fluids leaving a structure withinterconnected pores, or flow channels. Reduced pressure or fluid isdelivered to the flow channels. As new tissue develops, the tissue growsinto the pores of the reduced-pressure delivery apparatus 1035, and thenultimately replaces the reduced-pressure delivery apparatus 1035 as itdegrades. In this particular example, the reduced-pressure deliveryapparatus 1035 serves not only as a manifold, but also as a scaffold fornew tissue growth.

In another embodiment, the reduced-pressure delivery apparatus 1035 isan alginate mixed with 400 μm mannose beads. The poragens or beads maybe dissolved by local body fluids or by irrigational or other fluidsdelivered to the reduced-pressure delivery apparatus 1035 at the tissuesite. Following dissolution of the poragens or beads, the spacespreviously occupied by the poragens or beads become voids that areinterconnected with other voids to form the flow channels within thereduced-pressure delivery apparatus 1035.

The use of poragens to create flow channels in a material is effective,but it also forms pores and flow channels that are limited in size toapproximately the particle size of the selected poragen. Instead ofporagens, a chemical reaction may be used to create larger pores due tothe formation of gaseous by-products. For example, in one embodiment, aflowable material may be delivered to the tissue site 1025 that containssodium bicarbonate and citric acid particles (non-stoichiometric amountsmay be used). As the flowable material forms a foam or solid in situ,bodily fluids will initiate an acid-base reaction between the sodiumbicarbonate and the citric acid. The resulting carbon dioxide gasparticles that are produced create larger pore and flow channelsthroughout the reduced-pressure delivery apparatus 1035 than techniquesrelying on poragen dissolution.

The transformation of the reduced-pressure delivery apparatus 1035 froma liquid or viscous gel into a solid or a foam can be triggered by pH,temperature, light, or a reaction with bodily fluids, chemicals, orother substances delivered to the tissue site. The transformation mayalso occur by mixing multiple reactive components. In one embodiment,the reduced-pressure delivery apparatus 1035 is prepared by selectingbioresorbable microspheres made from any bioresorbable polymer. Themicrospheres are dispersed in a solution containing a photoinitiator anda hydrogel-forming material, such as hyaluronic acid, collagen, orpolyethylene glycol with photoreactive groups. The microsphere-gelmixture is exposed to light for a brief period of time to partiallycrosslink the hydrogel and immobilize the hydrogel on the microspheres.The excess solution is drained, and the microspheres are then dried. Themicrospheres are delivered to the tissue site by injection or pouring,and following delivery, the mixture absorbs moisture, and the hydrogelcoating becomes hydrated. The mixture is then again exposed to light,which cross-links the microspheres, creating a plurality of flowchannels. The cross-linked microspheres then serve as a manifold todeliver reduced pressure to the tissue site and as a porous scaffold topromote new tissue growth.

In addition to the preceding embodiments described herein, thereduced-pressure delivery apparatus 1035 may be made from a variety ofmaterials, including, without limitation, calcium phosphate, collagen,alginate, cellulose, or any other equivalent material that is capable ofbeing delivered to the tissue site as a gas, liquid, gel, paste, putty,slurry, suspension, or other flowable material and is capable of formingmultiple flow paths in fluid communication with the tissue site. Theflowable material may further include particulate solids, such as beads,that are capable of flowing through the manifold delivery tube 1021 ifthe particulate solids are sufficiently small in size. Materials thatare delivered to the tissue site in a flowable state may polymerize orgel in situ.

As previously described, the reduced-pressure delivery apparatus 1035may be injected or poured directly into the void 1029 adjacent thetissue site 1025. Referring primarily to FIG. 17A, the manifold deliverytube 1021 may include an impermeable or semi-permeable membrane 1051 atthe distal end 1043 of the manifold delivery tube 1021. The membrane1051 includes an inner space 1055 that fluidly communicates with asecondary lumen 1057 attached to the manifold delivery tube 1021. Themanifold delivery tube 1021 is guided to the tissue site 1025 over aguide wire 1061.

The reduced-pressure delivery apparatus 1035 may be injected or pouredthrough the secondary lumen 1057 to fill the inner space 1055 of themembrane 1051. As the fluid or gel fills the membrane 1051, the membrane1051 expands to fill the void 1029 such that the membrane is in contactwith the tissue site 1025. As the membrane 1051 expands, the membrane1051 may be used to dissect additional tissue adjacent or near thetissue site 1025. The membrane 1051, if impermeable, may be physicallyruptured and removed, leaving behind the reduced-pressure deliveryapparatus 1035 in contact with the tissue site 1025. Alternatively, themembrane 1051 may be made from a dissolvable material that dissolves inthe presence of bodily fluids or biocompatible solvents that may bedelivered to the membrane 1051. If the membrane 1051 is semi-permeable,the membrane 1051 may remain in situ. The semi-permeable membrane 1051allows communication of reduced pressure and possibly other fluids tothe tissue site 1025.

Referring primarily to FIG. 18, a method 1111 of administering areduced-pressure tissue treatment to a tissue site includes at 1115surgically inserting a manifold adjacent the tissue site, the manifoldhaving a plurality of projections extending from a flexible barrier tocreate a plurality of flow channels between the projections. Themanifold is positioned at 1119 such that at least a portion of theprojections are in contact with the tissue site. At 1123, a reducedpressure is applied through the manifold to the tissue site.

Referring primarily to FIG. 19, a method 1211 of administering areduced-pressure tissue treatment to a tissue site includes at 1215percutaneously inserting a manifold adjacent the tissue site. Themanifold may include a plurality of projections extending from aflexible barrier to create a plurality of flow channels between theprojections. Alternatively, the manifold may include cellular materialhaving a plurality of flow channels within the cellular material.Alternatively, the manifold may be formed from an injectable or pourablematerial that is delivered to the tissue site and forms a plurality offlow channels after arriving at the tissue site. At 1219, the manifoldis positioned such that at a least a portion of the flow channels are influid communication with the tissue site. A reduced pressure is appliedto the tissue site through the manifold at 1223.

Referring primarily to FIG. 20, a method 1311 of administering areduced-pressure tissue treatment to a tissue site includes at 1315percutaneously inserting a tube having a passageway through a tissue ofa patient to place a distal end of the tube adjacent the tissue site. At1319, a balloon associated with the tube may be inflated to dissecttissue adjacent the tissue site, thereby creating a void. At 1323, amanifold is delivered through the passageway. The manifold may include aplurality of projections extending from a flexible barrier to create aplurality of flow channels between the projections. Alternatively, themanifold may include cellular material having a plurality of flowchannels within the cellular material. Alternatively, the manifold maybe formed from an injectable or pourable material that is delivered tothe tissue site as described previously with reference to FIG. 17. Themanifold is positioned in the void at 1327 such that at least a portionof the flow channels are in fluid communication with the tissue site. At1331, a reduced pressure is applied to the tissue site through themanifold via a reduced-pressure delivery tube or any other deliverymeans.

Referring primarily to FIG. 21, a method 1411 of administering areduced-pressure tissue treatment to a tissue site includes at 1415percutaneously inserting a tube having a passageway through a tissue ofa patient to place a distal end of the tube adjacent the tissue site. At1423, a manifold is delivered through the passageway to the tissue sitewithin an impermeable sheath, the impermeable sheath at 1419 having beensubjected to a first reduced pressure less than an ambient pressure ofthe sheath. At 1427, the sheath is ruptured to place the manifold incontact with the tissue site. At 1431, a second reduced pressure isapplied through the manifold to the tissue site.

Referring primarily to FIGS. 22 and 23, a reduced-pressure deliveryapparatus 1511 according to an embodiment of the present disclosureincludes an orthopedic hip prosthesis 1515 for replacing the existingfemoral head of a femur 1517 of a patient. The hip prosthesis 1515includes a stem portion 1521 and a head portion 1525. The stem portion1521 is elongated for insertion within a passage 1529 reamed in a shaftof the femur 1517. A porous coating 1535 is disposed around the stemportion and preferably is constructed from sintered or vitrifiedceramics or metal. Alternatively, a cellular material having porouscharacteristic could be disposed around the stem portion. A plurality offlow channels 1541 is disposed within the stem portion 1521 of the hipprosthesis 1515 such that the flow channels 1541 are in fluidcommunication with the porous coating 1535. A connection port 1545 isfluidly connected to the flow channels 1541, the port being configuredfor releasable connection to a reduced-pressure delivery tube 1551 and areduced-pressure delivery source 1553. The flow channels 1541 are usedto deliver a reduced pressure to the porous coating 1535 or the bonesurrounding the hip prosthesis 1515 following implantation. The flowchannels 1541 may include a main feeder line 1543 that fluidlycommunicates with several lateral branch lines 1547, which communicatewith the porous coating 1535. The lateral branch lines 1547 may beoriented normal to the main feeder line 1543 as illustrated in FIG. 22,or may be oriented at angles to the main feeder line 1543. Analternative method for distributing the reduced pressure includesproviding a hollow hip prosthesis, and filling the inner space of theprosthesis with a cellular (preferably open-cell) material that iscapable of fluidly communicating with the porous coating 1535.

Referring more specifically to FIG. 23, hip prosthesis 1515 may furtherinclude a second plurality of flow channels 1561 within the stem portion1521 to provide a fluid to the porous coating 1535 or the bonesurrounding the hip prosthesis 1515. The fluid could include filteredair or other gases, antibacterial agents, antiviral agents, cell-growthpromotion agents, irrigation fluids, chemically active fluids, or anyother fluid. If it is desired to introduce multiple fluids to the bonesurrounding the hip prosthesis 1515, additional paths of fluidcommunication may be provided. A connection port 1565 is fluidlyconnected to the flow channels 1561, the connection port 1565 beingconfigured for releasable connection to a fluid delivery tube 1571 and afluid delivery source 1573. The flow channels 1561 may include a mainfeeder line 1583 that fluidly communicates with several lateral branchlines 1585, which communicate with the porous coating 1535. The lateralbranch lines 1585 may be oriented normal to the main feeder line 1583 asillustrated in FIG. 23, or may be oriented at angles to the main feederline 1583.

The delivery of reduced pressure to the first plurality of flow channels1541 and the delivery of the fluid to the second plurality of flowchannels 1561 may be accomplished by separate tubes, such asreduced-pressure delivery tube 1551 and fluid delivery tube 1571.Alternatively, a tube having multiple lumens as described previouslyherein may be used to separate the communication paths for deliveringthe reduced pressure and the fluid. It should further be noted thatwhile it is preferred to provide separate paths of fluid communicationwithin the hip prosthesis 1515, the first plurality of flow channels1541 could be used to deliver both the reduced pressure and the fluid tothe bone surrounding the hip prosthesis 1515.

As previously described, application of reduced pressure to bone tissuepromotes and speeds the growth of new bone tissue. By using the hipprosthesis 1515 as a manifold to deliver reduced pressure to the area ofbone surrounding the hip prosthesis, recovery of the femur 1517 isfaster, and the hip prosthesis 1515 integrates more successfully withthe bone. Providing the second plurality of flow channels 1561 to ventthe bone surrounding the hip prosthesis 1515 improves the successfulgeneration of new bone around the prosthesis.

Following the application of reduced pressure through the hip prosthesis1515 for a selected amount of time, the reduced-pressure delivery tube1551 and fluid delivery tube 1571 may be disconnected from theconnection ports 1545, 1565 and removed from the patient's body,preferably without a surgically-invasive procedure. The connectionbetween the connection ports 1545, 1565 and the tubes 1551, 1571 may bea manually-releasable connection that is effectuated by applying anaxially-oriented tensile force to the tubes 1551, 1571 on the outside ofthe patient's body. Alternatively, the connection ports 1545, 1565 maybe bioresorbable or dissolvable in the presence of selected fluids orchemicals such that release of the tubes 1551, 1571 may be obtained byexposing the connection ports 1545, 1565 to the fluid or chemical. Thetubes 1551, 1571 may also be made from a bioresorbable material thatdissolves over a period of time or an activated material that dissolvesin the presence of a particular chemical or other substance.

The reduced-pressure delivery source 1553 may be provided outside thepatient's body and connected to the reduced-pressure delivery tube 1551to deliver reduced pressure to the hip prosthesis 1515. Alternatively,the reduced-pressure delivery source 1553 may be implanted within thepatient's body, either on-board or near the hip prosthesis 1515.Placement of the reduced-pressure delivery source 1553 within thepatient's body eliminates the need for a percutaneous fluid connection.The implanted reduced-pressure delivery source 1553 may be a traditionalpump that is operably connected to the flow channels 1541. The pump maybe powered by a battery that is implanted within the patient, or may bepowered by an external battery that is electrically and percutaneouslyconnected to the pump. The pump may also be driven directly by achemical reaction that delivers a reduced pressure and circulates fluidsthrough the flow channels 1541, 1561.

While only the stem portion 1521 and head portion 1525 of the hipprosthesis 1515 are illustrated in FIGS. 22 and 23, it should be notedthat the flow channels and means for applying reduced-pressure tissuetreatment described herein could be applied to any component of the hipprosthesis 1515 that contacts bone or other tissue, including, forexample, the acetabular cup.

Referring primarily to FIG. 24, a method 1611 for repairing a joint of apatient includes at 1615 implanting a prosthesis within a bone adjacentthe joint. The prosthesis could be a hip prosthesis as described aboveor any other prosthesis that assists in restoring mobility to the jointof the patient. The prosthesis includes a plurality of flow channelsconfigured to fluidly communicate with the bone. At 1619, a reducedpressure is applied to the bone through the plurality of flow channelsto improve oseointegration of the prosthesis.

Referring primarily to FIGS. 25 and 26, a reduced-pressure deliveryapparatus 1711 according to an embodiment of the present disclosureincludes an orthopedic fixation device 1715 for securing a bone 1717 ofa patient that includes a fracture 1719 or other defect. The orthopedicfixation device 1715 illustrated in FIGS. 25 and 26 is a plate having aplurality of passages 1721 for anchoring the orthopedic fixation device1715 to the bone 1717 with screws 1725, pins, bolts, or other fasteners.A porous coating 1735 may be disposed on a surface of the orthopedicfixation device 1715 that is to contact the bone 1717. The porouscoating is preferably constructed from sintered or vitrified ceramics ormetal. Alternatively, a cellular material having porous characteristiccould be disposed between the bone 1717 and the orthopedic fixationdevice 1715. A plurality of flow channels 1741 is disposed within theorthopedic fixation device 1715 such that the flow channels 1741 are influid communication with the porous coating 1735. A connection port 1745is fluidly connected to the flow channels 1741, the port beingconfigured for connection to a reduced-pressure delivery tube 1751 and areduced-pressure delivery source 1753. The flow channels 1741 are usedto deliver a reduced pressure to the porous coating 1735 or the bonesurrounding the orthopedic fixation device 1715 following fixation ofthe orthopedic fixation device 1715 to the bone 1717. The flow channels1741 may include a main feeder line 1743 that fluidly communicates withseveral lateral branch lines 1747, which communicate with the porouscoating 1735. The lateral branch lines 1747 may be oriented normal tothe main feeder line 1743 as illustrated in FIG. 25, or may be orientedat angles to the main feeder line 1743. An alternative method fordistributing the reduced pressure includes providing a hollow orthopedicfixation device, and filling the inner space of the orthopedic fixationdevice with a cellular (preferably open-cell) material that is capableof fluidly communicating with the porous coating 1735.

The orthopedic fixation device 1715 may be a plate as shown in FIG. 25,or alternatively may be a fixation device, such as a sleeve, a brace, astrut, or any other device that is used to stabilize a portion of thebone. The orthopedic fixation device 1715 may further be fasteners usedto attach prosthetic or other orthopedic devices or implanted tissues(e.g., bone tissues or cartilage), provided that the fasteners includeflow channels for delivering reduced pressure to tissue adjacent to orsurrounding the fasteners. Examples of these fasteners may include pins,bolts, screws, or any other suitable fastener.

Referring more specifically to FIG. 26, the orthopedic fixation device1715 may further include a second plurality of flow channels 1761 withinthe orthopedic fixation device 1715 to provide a fluid to the porouscoating 1735 or the bone surrounding the orthopedic fixation device1715. The fluid could include filtered air or other gases, antibacterialagents, antiviral agents, cell-growth promotion agents, irrigationfluids, chemically active agents, or any other fluid. If it is desiredto introduce multiple fluids to the bone surrounding the orthopedicfixation device 1715, additional paths of fluid communication may beprovided. A connection port 1765 is fluidly connected to the flowchannels 1761, the connection port 1765 being configured for connectionto a fluid delivery tube 1771 and a fluid delivery source 1773. The flowchannels 1761 may include a main feeder line 1783 that fluidlycommunicates with several lateral branch lines 1785, which communicatewith the porous coating 1735. The lateral branch lines 1785 may beoriented normal to the main feeder line 1783 as illustrated in FIG. 23,or may be oriented at angles to the main feeder line 1783.

The delivery of reduced pressure to the first plurality of flow channels1741 and the delivery of the fluid to the second plurality of flowchannels 1761 may be accomplished by separate tubes, such asreduced-pressure delivery tube 1751 and fluid delivery tube 1771.Alternatively, a tube having multiple lumens as described previouslyherein may be used to separate the communication paths for deliveringthe reduced pressure and the fluid. It should further be noted thatwhile it is preferred to provide separate paths of fluid communicationwithin the orthopedic fixation device 1715, the first plurality of flowchannels 1741 could be used to deliver both the reduced pressure and thefluid to the bone adjacent the orthopedic fixation device 1715.

The use of orthopedic fixation device 1715 as a manifold to deliverreduced pressure to the area of bone adjacent the orthopedic fixationdevice 1715 speeds and improves recovery of the fracture 1719 of thebone 1717. Providing the second plurality of flow channels 1761 tocommunicate fluids to the bone surrounding the orthopedic fixationdevice 1715 improves the successful generation of new bone near theorthopedic fixation device.

Referring primarily to FIG. 27, a method 1811 for healing a bone defectof a bone includes at 1815 fixating the bone using an orthopedicfixation device. The orthopedic fixation device includes a plurality offlow channels disposed within the orthopedic fixation device. At 1819, areduced pressure is applied to the bone defect through the plurality offlow channels.

Referring primarily to FIG. 28, a method 1911 for administeringreduced-pressure tissue treatment to a tissue site includes at 1915positioning a manifold having a plurality of flow channels such that atleast a portion of the flow channels are in fluid communication with thetissue site. A reduced pressure is applied at 1919 to the tissue sitethrough the flow channels, and a fluid is delivered at 1923 to thetissue site through the flow channels.

Referring primarily to FIG. 29, a method 2011 for administeringreduced-pressure tissue treatment to a tissue site includes at 2015positioning a distal end of a manifold delivery tube adjacent the tissuesite. At 2019 a fluid is delivered through the manifold delivery tube tothe tissue site. The fluid is capable of filling a void adjacent thetissue site and becoming a solid manifold having a plurality of flowchannels in fluid communication with the tissue site. A reduced pressureis applied at 2023 to the tissue site through the flow channels of thesolid manifold.

Referring primarily to FIGS. 30-38, a reduced-pressure delivery system2111 includes a primary manifold 2115 having a wall 2117 surrounding aprimary flow passage 2121. The wall 2117 is connected at a proximal end2123 to a reduced-pressure delivery tube 2125. Since the shape of thereduced-pressure delivery tube 2125 will typically be round incross-section, and since the shape of the primary manifold 2115 incross-section may be other than round (i.e. rectangular in FIGS. 30-35and triangular in FIGS. 36-38), a transition region 2129 is providedbetween the reduced-pressure delivery tube 2125 and the primary manifold2115. The primary manifold 2115 may be adhesively connected to thereduced-pressure delivery tube 2125, connected using other means, suchas fusing or insert molding, or alternatively may be integrallyconnected by co-extrusion. The reduced-pressure delivery tube 2125delivers reduced pressure to the primary manifold 2115 for distributionat or near the tissue site.

The wall 2117 may be made from a flexible material, a rigid material, ora combination of both flexible and rigid materials. For example, amedical grade silicone polymer or other flexible materials may bemolded, extruded, or otherwise manufactured to form a flexible wall2117. Alternatively, rigid materials including but not limit to metals,polyvinylchloride (PVC), polyurethane, and other rigid polymericmaterials may be molded, extruded, or otherwise manufactured to form arigid wall 2117.

A blockage prevention member 2135 is positioned within the primarymanifold to prevent collapse of the primary manifold 2115, and thusblockage of the primary flow passage 2121 during application of reducedpressure. In one embodiment, the blockage prevention member 2135 may bea plurality of projections 2137 (see FIG. 34) disposed on an innersurface 2141 of the wall 2117 and extending into the primary flowpassage 2121. In another embodiment, the blockage prevention member 2135may be a single or multiple ridges 2145 disposed on the inner surface2141 (see FIGS. 30 and 31). In yet another embodiment, the blockageprevention member 2135 may include a cellular material 2149 disposedwithin the primary flow passage, such as that illustrated in FIG. 37.The blockage prevention member 2135 may be any material or structurethat is capable of being inserted within the flow passage or that iscapable of being integrally or otherwise attached to the wall 2117. Whenthe wall 2117 is made from a flexible material, the blockage preventionmember 2135 is able to prevent total collapse of the wall 2117, whilestill allowing the flow of fluids through the primary flow passage 2121.

The wall 2117 further includes a plurality of apertures 2155 through thewall 2117 that communicate with the primary flow passage 2121. Theapertures 2155 allow reduced pressure delivered to the primary flowpassage 2121 to be distributed to the tissue site. Apertures 2155 may beselectively positioned around the circumference of the primary manifold2115 to preferentially direct the delivery of vacuum.

The reduced-pressure delivery tube 2125 preferably includes a firstconduit 2161 having at least one outlet fluidly connected to the primaryflow passage 2121 to deliver reduced pressure to the primary flowpassage 2121. A second conduit 2163 may also be provided to purge theprimary flow passage 2121 and the first conduit 2161 with a fluid toprevent or resolve blockages caused by wound exudate and other fluidsdrawn from the tissue site. The second conduit 2163 preferably includesat least one outlet positioned proximate to at least one of the primaryflow passage 2121 and the at least one outlet of the first conduit 2161.

Referring more specifically to FIGS. 30 and 31, the reduced-pressuredelivery system 2111 may include multiple conduits for purging theprimary flow passage 2121 and the first conduit 2161. While the end ofthe wall 2117 opposite the end attached to reduced-pressure deliverytube 2125 may be open as illustrated in FIG. 30, it has been found thatcapping the end of the wall 2117 may improve the performance andreliability of the purging function. Preferably, a head space 2171 isprovided for between the capped end of the wall and the end of thesecond conduit 2163. The head space 2171 allows for a buildup of purgefluid during the purging process, which helps drive the purge fluidthrough the primary flow passage 2121 and into the first conduit 2161.

Also illustrated in FIG. 31 is the divider that serves as the blockageprevention member 2135. The centrally-located divider bifurcates theprimary flow passage 2121 into two chambers, which allows continuedoperation of the primary manifold 2115 if one of the chambers becomesblocked and purging is unable to resolve the blockage.

Referring primarily to FIGS. 39 and 40, a reduced-pressure deliverysystem 2211 includes a primary manifold 2215 that is integral to areduced-pressure delivery tube 2217. The reduced-pressure delivery tube2217 includes a central lumen 2223 and a plurality of ancillary lumens2225. While the ancillary lumens 2225 may be used to measure pressure ator near the tissue site, the ancillary lumens 2225 may further be usedto purge the central lumen 2223 to prevent or resolve blockages. Aplurality of apertures 2231 communicate with the central lumen 2223 todistribute the reduced pressure delivered by the central lumen 2223. Asillustrated in FIG. 40, it is preferred that the apertures 2231 notpenetrate the ancillary lumens 2225. Also illustrated in FIG. 40 is thecountersunk end of the reduced-pressure delivery tube, which creates ahead space 2241 beyond the end of the ancillary lumens 2225. If tissue,scaffolds, or other materials were to engage the end of thereduced-pressure delivery tube 2217 during application of reducedpressure, the head space 2241 would continue to allow purging fluid,which may be a liquid or gas, to be delivered to the central lumen 2223.

In operation, the reduced-pressure delivery systems 2111, 2211 of FIGS.30-40 may be applied directly to a tissue site for distributing reducedpressure to the tissue site. The low-profile shape of the primarymanifolds is highly desirous for the percutaneous installation andremoval techniques described herein. Similarly, the primary manifoldsmay also be inserted surgically.

Referring now primarily to FIGS. 41 and 42, a manifold 5115 is shownaccording to an illustrative embodiment. FIG. 42 is a longitudinalcross-sectional view of the manifold 5115. The manifold 5115 is adaptedto be inserted into a patient and placed at the subcutaneous tissuesite. The manifold 5115 includes a plurality of first conduits 5121 thatare adjacent to one another to form an interior space that defines asecond conduit 5163 between the first conduits 5121. The plurality offirst conduits 5121 may be spaced in a uniform pattern or an irregularpattern and the members of the first plurality of conduits 5121 may beuniform in size or vary. The first conduits 5115 may be coupled one toanother by a plurality of bonds, e.g., welds, cement, bonds, etc. Themanifold 5115 provides a reduced-pressure supply function and purgingfunction using the first conduits 5121 and second conduit 5163. In onenon-limiting example, the second conduit 5163 may communicate with eachof the first conduits 5121 via a plurality of second apertures 5140.

The manifold 5115 includes first conduits 5121. Each of the firstconduits 5121 has at least one first aperture 5131 and at least onesecond aperture 5140 formed in a wall 5125, e.g., an annular wall. Inthe non-limiting examples of FIGS. 51 and 52, each of the first conduits5121 has a plurality of first apertures 5131 and a plurality of secondapertures 5140 formed in the wall 5125. The first apertures 5131 may beuniformly or non-uniformly spaced from one another and may be uniform ornon-uniform in diameter. Also, the second apertures 5140 may beuniformly or non-uniformly spaced from one another and may be uniform ornon-uniform in diameter.

In one illustrative embodiment, at least one of the first conduits 5121is in fluid communication with a reduced-pressure source, such as thereduced-pressure source 427 in FIG. 9. At least one of the firstconduits 5121 may deliver reduced pressure from the reduced-pressuresource to a tissue site via the first apertures 5131. The first conduits5121 may also deliver reduced pressure to any portion of the manifold5115, such as a distal end 5182 of the manifold 5115. In anotherillustrative embodiment, each of the first conduits 5121 is in fluidcommunication with a reduced-pressure source, and each of first conduits5121 delivers reduced pressure to a subcutaneous tissue site via thefirst apertures 5131. The flow of fluid in a direction away from thedistal end 5182 of the manifold 5115 through the first conduits 5121 isrepresented by the arrows 5171. The flow of fluid away from the manifold5115 in this manner causes a reduced pressure at the first conduits 5121or at least a portion of the first conduits to be transferred to atissue site via the first apertures 5131.

Each the first apertures 5131 allow fluid communication between thefirst conduits 5121 and a space outside of the manifold 5115, such as atissue site. In addition to permitting the transfer of reduced pressurefrom the first conduits 5121 to a tissue site, the first apertures 5131may also allow exudate or other fluid from the tissue site to enter thefirst conduits 5121. The flow of fluid from the space outside of themanifold 5115 into the first conduits 5121 is represented by arrows5172.

The first conduits 5121 are shown with a circular cross-sectional shape.However, the first conduits 5121 may have any cross-sectional shape,including an elliptical, diamond, triangular, square, polygonal, etc.

In addition, although FIG. 41 shows the manifold 5115 having four firstconduits 5121, the manifold 5115 may have any number of first conduits.For example, the manifold 5115 may have two or more first conduits 5121that at least partially encompass and form the second conduit 5163. Thesecond conduit 5163 may be centrally disposed between the two or morefirst conduits 5121 and typically between at least three of the firstconduits 5121.

Each of the first apertures 5131 is shown to have a circularcross-sectional shape. However, each of the first apertures 5131 mayhave any cross-sectional shape, such as an elliptical or polygonalcross-sectional shape. In another example, each of the first apertures5131 may be slits that extend along all or a portion of the firstconduits 5121. As used herein, a “slit” is any elongated hole, aperture,or channel. In one illustrative embodiment, each of the slits may besubstantially parallel to one another.

The second conduit 5163 of the manifold 5115 is formed by a portion ofeach of the outer surfaces 5184 and 5186 of the first conduits 5121.Each of the second apertures 5140 is located on the portion of each ofthe outer surfaces 5184 and 5186 of the first conduits 5121 that formthe second conduit 5163. The second conduit 5163 is typically centrallyformed, or otherwise disposed, between the first conduits 5121. Thesecond conduit 5163 is in fluid communication with the first conduits5121 via the second apertures 5140.

The second conduit 5163 may be in fluid communication with a fluidsource (not shown) that supplies a fluid to the tissue site or portionsof the first conduit 5121. The second conduit 5163 may receive fluidfrom the fluid source. In one embodiment, the second conduit 5163delivers the fluid to each of the first conduits 5121 via the secondapertures 5140. The second conduit 5163 may also deliver a fluid to adistal portion of the manifold 5115, including the end of the manifold5115. The second conduit 5163 may also deliver a fluid to the tissuespace around the manifold 5115. The fluid delivered by the secondconduit 5163 may be a gas, such as air, or a liquid. The flow of fluiddelivered by the second conduit 5163 is represented by arrows 5173. Inan alternative embodiment, fluid from a fluid source may be deliveredtoward the distal end 5182 of the manifold 5115 by any one or more ofthe first conduits 5121.

In one non-limiting embodiment, the first conduits 5121 draw fluid fromthe second conduit 5163 via the second apertures 5140. In thisembodiment, reduced pressure from a reduced-pressure source causes thefluid to be drawn from the second conduit 5163 to the first conduits5121 via the second apertures 5140. In another non-limiting embodiment,positive pressure provided by the fluid source and delivered by thesecond conduit 5163 forces, or otherwise causes, the fluid to betransferred from the second conduit 5163 to the first conduits 5121 viathe second apertures 5140. The transfer of fluid from the second conduit5163 to the first conduits 5121 via the second apertures 5140facilitates the purging function of the manifold 5115 that helps toremove or reduce any blockages that form in the manifold 5115. The firstconduits 5121 may include any number of second apertures 5140, whichnumber may control the rate of fluid being transferred from the secondconduit 5163 to the first conduits 5121.

In one embodiment, the manifold 5115 may also include an end cap 5170that is adapted to be coupled or is coupled to the distal end 5182 ofthe manifold 5115 to form a distribution space. Fluid delivered by thesecond conduit 5163 may be transferred from the second conduit 5163 tothe first conduits 5121 via the space that is formed by coupling the endcap 5170 to the distal end 5182 of the manifold 5115. In one embodiment,the space may provide the sole passageway through which fluid istransferred from the second conduit 5163 to the first conduits 5121. Inthis embodiment, no second apertures 5140 may be present on the firstconduits 5121 or a minimal number of apertures 5140.

In one illustrative embodiment, the second apertures 5140 are absent ornot open to the outside of the manifold 5115 and fluid, such as liquidor air, may be drawn into the second conduit 5163 by opening a valve toatmosphere (e.g., air purge). The valve is in fluid communication withthe second conduit 5163. Thus, fluid may be drawn through the secondconduit 5163 and back toward a reduced-pressure device via the firstconduits 5121, which, while under reduced pressure, may supply the forceto draw any clot/clog formations, such as fibrin formations, out of themanifold 5115 and toward the reduced-pressure source. In thisembodiment, no supply port for the second conduit 5163 may be present onthe outer surface of the manifold 5115. In this illustrative embodiment,the second conduit 5163 may be completely enclosed by the first conduits5121, including a distal end of the second conduit 5163, and thus may beclosed from an outside environment, such as a tissue space. The secondconduit 5163 communicates proximate end cap 5170 from the second conduit5163 to the first conduits 5121. This illustrative embodiment may allowfor a fluid to be contained within the manifold 5115 as the fluid movesfrom the second conduit 5163 to the first conduits 5121. Thus, in thisembodiment, the likelihood of the fluid moving out into the tissue spaceis reduced or eliminated.

In one illustrative, non-limiting embodiment, the manifold 5115 isformed with four of the first conduits 5121. As before, the firstconduits 5121 form the second conduit 5163. Each of the four firstconduits 5121 touch at least two other of the four first conduits 5121.In this embodiment, the four first conduits 5121 and second conduit 5163are formed by co-extruding the conduits 5121, 5163. After the extrudingthe conduits 5121, 5163, a core pin may be used to pierce the conduitsstraight through to form the first apertures 5131. Thus, for example, acore pin may pierce the upper right (for the orientation in FIG. 41)first conduit 5121 and the lower left first conduit 5121—andconcomitantly pierce the second conduit 5163. This may be repeated asmany times as desired and at various orientations.

In the example in which the fluid in second conduit 5163 is a liquid,the liquid may be pumped in or gravity fed down the second conduit 5163such that the only pathway for the liquid is through the secondapertures 5140 and into the first conduits 5121, along the firstconduits 5121, and toward the reduced-pressure source. The manifold 5115preferably has a symmetrical design, and the symmetrical design of themanifold 5115 allows the manifold 5115 to be used in any spatialorientation to achieve the same or similar results in each position.

In another illustrative embodiment, a supplied fluid may be allowed toenter the space surrounding the manifold 5115, such as a tissue space.For example, the fluid may exit the manifold 5115 at the opening at thedistal end 5182 of the second conduit 5163. The fluid may then be drawninto the first conduits 5121.

In one illustrative embodiment, a method for applying reduced pressureto a subcutaneous tissue site includes applying the manifold 5115 to thesubcutaneous tissue site. The manifold 5115 may be percutaneouslyinserted into a patient, and the manifold 5115 may be positionedadjacent to or abutting the subcutaneous tissue site. The symmetricaldesign of the manifold 5115 may facilitate the implantation of themanifold in any orientation.

In one illustrative embodiment, a method of manufacturing an apparatusfor applying reduced pressure to a subcutaneous tissue site includesproviding first conduits 5121. The method may also include coupling thefirst conduits 5121 to one another to form the second conduit 5163. Thesecond conduit 5163 is formed by a portion of each outer surface 5184and 5186 of the first conduits 5121. The method may also includeproviding a delivery conduit for delivering reduced pressure to at leastone of the first conduits 5121. The method may also include fluidlycoupling the delivery conduit to the first conduits 5121 and the secondconduit 5163.

Referring now primarily to FIG. 43, another illustrative, non-limitingembodiment of the manifold 5115 is presented. The manifold 5115 includesthe plurality of first conduits 5121 that are coupled in a spacedrelationship with a plurality of bonds 5117. Each of the plurality offirst conduits 5121 may have differing diameters or the same diameters,and in this illustrative embodiment, one conduit 5123 of the firstconduits conduit 5121 is shown with a smaller diameter than the others.It should be understood in this and the other illustrative embodimentsthat the diameter of the first conduits may be varied or may be uniform.

The manifold 5115 includes the second conduit 5163 formed by a portionof each of the outer surfaces 5184 of the first conduits 5121. Thesecond conduit 5163 is shown with broken lines and in this illustrationis a star-like shape. One or more additional conduits, such as thirdconduit 5165, may be disposed within the second conduit 5163. Theadditional conduit 5165 may be sized to touch each of the plurality offirst conduits 5121 as shown or may be smaller in size. The additionalconduit, or third conduit 5165, may be coupled to one or more of thefirst conduits 5121. In an alternative embodiment (not shown), the firstconduits 5121 may not form or fully form the second conduit, but themanifold 5115 may have the additional conduit 5165 at a center positionadjacent to each of the first conduits 5121.

The additional conduit 5165 may carry a purging fluid or may be used tocarry other fluids to or from a distal end (not shown) of the manifold5115. The space 5167 formed exterior to the additional conduit 5165 andon the interior of the second conduit 5163 may carry a purging fluid tobe introduced through apertures in the outer wall portion 5184 of thefirst conduits 5121, and the additional conduit 5165 may carry a purgingfluid to an end cap (e.g., end cap 5170 in FIG. 42) to introduce apurging fluid into the first conduits 5121 at the distal end. The endcap 5170 may be attached to the distal end 5182 using interference fit,RF welding, RF formed tip process, solvent bonding, or any othercoupling technique.

Referring primarily to FIGS. 44A and 44B, a manifold 5315 is shownaccording to an illustrative embodiment. The manifold 5315 includespurging lumen 5363 and reduced-pressure lumens 5321 that are at leastpartially separated by lumen walls 5380. In one non-limiting example,the purging lumen 5363 may communicate with each of the reduced-pressurelumens 5321 via the interlumen channels 5340 and head space 5371.

The manifold 5315 includes reduced-pressure lumens 5321 to transferreduced pressure from a reduced-pressure source. The reduced-pressurelumens 5321 deliver reduced pressure from a reduced-pressure source to atissue site, or any portion of the manifold 5315. The flow of fluid in adirection away from the end 5382 of the manifold 5315 through thereduced-pressure lumens 5321 is represented by the arrows 5369. The flowof fluid away from the manifold 5315 in this manner causes a reducedpressure at the reduced-pressure lumens 5321 that may be transferred toa tissue site, as well as other portions of the manifold 5315. Thereduced-pressure lumens 5321 may have any cross-sectional shape,including a circular, elliptical, flattened, irregular, or polygonalcross-sectional shape. In one example, the material from which themanifold 5315 is made may be flexible, causing the cross-sectional shapeof the reduced-pressure lumens 5321 to vary depending on fluid flowthrough the lumens. In addition, although FIGS. 44A and 44B show themanifold 5315 to have two reduced-pressure lumens 5321, the manifold5315 may have any number of reduced-pressure lumens depending on theparticular implementation.

The reduced-pressure lumens 5321 also include apertures 5331. Reducedpressure from a reduced-pressure source may be delivered to a tissuesite via the apertures 5331 of the reduced-pressure lumens 5321. Each ofthe apertures 5331 allows fluid communication between thereduced-pressure lumens 5321 and a space outside of the manifold 5315,such as a tissue site. In addition to permitting the transfer of reducedpressure from the reduced-pressure lumens 5321 to a tissue site, theapertures 5331 may also allow exudate or other fluid from the tissuesite to enter the reduced-pressure lumens 5321. The flow of fluid fromthe space outside of the manifold 5315 into the reduced-pressure lumens5321 is represented by arrows 5372.

Each of the apertures 5331 may have a circular cross-sectional shape.However, each of the apertures 5331 may have any cross-sectional shape,such as an elliptical, polygonal, irregular cross-sectional shape. Inanother example, each of the apertures 5331 may be slits that extendalong all or a portion of the reduced-pressure lumens 5321. In thisexample, each of the slits may be substantially parallel to one another.

The manifold 5315 also includes purging lumen 5363. The purging lumen5363 is centrally disposed between the reduced-pressure lumens 5321. Thepurging lumen 5363, which is another non-limiting embodiment of thesecond conduit 2163 in FIGS. 30 and 31, is operable to deliver a fluidto a distal portion of the manifold 5315, including the end 5382 of themanifold 5315. The purging lumen 5363 may also deliver a fluid to thetissue space around the manifold 5315. The fluid delivered by thepurging lumen 5363 may be a gas, such as air, or a liquid. The flow offluid delivered by the purging lumen 5363 is represented by arrows 5373.

The purging lumen 5363 may have any cross-sectional shape, including ancircular, elliptical, flattened, irregular, or polygonal cross-sectionalshape. In one example, the material from which the manifold 5315 is mademay be flexible, causing the cross-sectional shape of the purging lumen5363 to vary depending on fluid flow through the lumen, as well as otherfactors. Although one purging lumen 5363 is shown, the manifold 5315 mayinclude any number of purging lumens.

The purging lumen 5363 is separated from the reduced-pressure lumens5321 by lumens walls 5380, which may be flexible or rigid. The lumenswalls 5380 include interlumen channels 5340. The interlumen channels5340 fluidly connect, or otherwise provide fluid communication between,the purging lumen 5363 and the reduced-pressure lumens 5321. In oneexample, the reduced-pressure lumens 5321 draw purging fluid from thepurging lumen 5363 via the interlumen channels 5340. In another example,positive pressure in the purging lumen 5363 forces the fluid from thepurging lumen 5363 to the reduced-pressure lumens 5321 via theinterlumen channels 5340. The positive pressure in the purging lumen5363 may be supplied by a positive pressure source. The lumen walls 5380may include any number of interlumen channels 5340, which number maycontrol the rate of fluid being transferred from the purging lumen 5363to the reduced-pressure lumens 5321.

In another example, the transfer of fluid from the purging lumen 5363 tothe reduced-pressure lumen 5321 may occur via the head space 5371 thatis formed by coupling an end of the manifold 5315 to the end cap 5370.In one embodiment, the head space may provide the sole passagewaythrough which fluid is transferred from the purging lumen 5363 to thereduced-pressure lumens 5321. In this embodiment, no interlumen channels5340 may be present in the manifold 5315. To facilitate the transfer offluid from the purging lumen 5363 to the reduced-pressure lumens 5321,the lumens walls 5380 may terminate without touching the end cap 5370 toform the head space 5371.

Referring primarily to FIGS. 45 and 46, a manifold 5415 is shownaccording to an illustrative embodiment. FIG. 46 is a cross-sectionalview of manifold 5415 taken along line 46-46 in FIG. 45. The manifold5415 includes sheets 5580 and 5581. A perimeter 5590 of the sheet 5580is attached to a perimeter 5592 of the sheet 5581 to form a pouch. Themanifold 5415 also includes a reduced-pressure cavity 5421 that is atleast partially enclosed by the pouch. The purging tube 5463 extendsinto the pouch.

The sheets 5580 and 5581 may be made from any material, and may be rigidor flexible. In one example, the sheets 5580 and 5581 are composed ofsilicone. The low-profile, and potentially flexible, nature of themanifold 5415 facilitates the movement and placement of the manifold5415 at a subcutaneous tissue site. The low profile of the manifold 5415may also ease percutaneous removal of the manifold 5415. The pouch thatis formed from the coupling between the sheets 5580 and 5581 is shown inFIG. 45 to have a “U” shape. The cross-sectional view of FIG. 46 showsthe sheets 5580 and 5581 to have an oval or “eye” shape. However, thepouch may also have any shape depending on the implementation, such as acircular, polygonal, or irregular shape. In one example, the materialfrom which the pouch is made may be flexible, causing thecross-sectional shape of the pouch, and therefore the reduced-pressurecavity 5421, to vary depending on fluid flow through the cavity, as wellas other factors.

In one example, a perimeter 5590 of the sheet 5580 is fixedly attachedto a perimeter 5592 of the sheet 5581 to form seams 5479. Alternatively,no seams may be present as a result of the coupling between the sheets5580 and 5581. In another example, the sheets 5580 and 5581 are notseparate sheets, but are formed from a single continuous piece ofmaterial.

The reduced-pressure cavity 5421 transfers reduced pressure from areduced-pressure source. The reduced-pressure cavity 5421 may deliverreduced pressure from a reduced-pressure source to a tissue site, or anyportion of the manifold 5415. The flow of fluid away from the end 5482of manifold 5415 through the reduced-pressure cavity 5421 is representedby the arrows 5469. The flow of fluid away from the manifold 5415 inthis manner causes a reduced pressure at the reduced-pressure cavity5421 that may be transferred to a tissue site, as well as other portionsof the manifold 5415.

The sheets 5580 and 5581 include apertures 5531. Reduced pressure from areduced-pressure source may be delivered to a tissue site via theapertures 5531. Each the apertures 5531 allow fluid communicationbetween the reduced-pressure cavity 5421 and a space outside of themanifold 5415, such as a tissue site. In addition to permitting thetransfer of reduced pressure from the reduced-pressure cavity 5421 to atissue site, the apertures 5531 may also allow exudate or other fluidfrom the tissue site to enter the reduced-pressure cavity 5421. The flowof fluid from the space outside of the manifold 5415 into thereduced-pressure cavity 5421 is represented by arrows 5572.

Each of the apertures 5531 may have a circular cross-sectional shape.However, each of the apertures 5531 may have any cross-sectional shape,such as an elliptical, polygonal, irregular cross-sectional shape. Inanother example, each of the apertures 5531 may be slits that extendalong all or a portion of the sheets 5580 and 5581. In this example,each of the slits may be substantially parallel to one another. Althoughthe apertures 5531 are shown to be included on both the sheets 5580 and5581, the apertures 5531 may also be included on only one of the sheets5580 and 5581.

The purging tube 5463 is disposed within the pouch formed by the sheets5580 and 5581. The purging tube 5463, which is another non-limitingembodiment of the second conduit 2163 in FIGS. 30 and 31, is operable todeliver a fluid to a distal portion of the manifold 5415, including theend 5482 of the manifold 5415. The purging tube 5463 may also deliver afluid to the tissue space around the manifold 5415. The fluid deliveredby the purging lumen 5463 may be a gas, such as air, or a liquid. Theflow of fluid delivered by the purging lumen 5463 is represented byarrows 5473.

The purging tube 5463 may have any cross-sectional shape, including ancircular, elliptical, flattened, irregular, or polygonal cross-sectionalshape. In one example, the material from which the purging tube 5463 ismade may be flexible, causing the cross-sectional shape of the purgingtube 5463 to vary depending on fluid flow through the tube, as well asother factors. Although one purging tube 5463 is shown, the manifold5415 may include any number of purging lumens.

The purging tube 5463 includes interlumen channels 5440. The interlumenchannels 5440 fluidly connect, or otherwise provide fluid communicationbetween, the purging tube 5463 and the reduced-pressure cavity 5421. Inone example, the reduced-pressure cavity 5421 draws purging fluid fromthe purging tube 5463 via the interlumen channels 5440. In anotherexample, positive pressure in the purging tube 5463 forces the fluidfrom the purging tube 5463 to the reduced-pressure cavity 5421 via theinterlumen channels 5440. The positive pressure in the purging tube 5463may be supplied by a positive pressure source. The purging tube 5463 mayinclude any number of interlumen channels 5440, which number may controlthe rate of fluid being transferred from the purging tube 5463 to thereduced-pressure cavity 5421.

In another example, the transfer of fluid from the purging tube 5463 tothe reduced-pressure cavity 5421 may occur via the head space 5471. Inthis example, no end cap, such as the end cap 5470, may be placed on anend of the purging tube 5463 so that the fluid from the purging tube5463 may enter the head space 5471. In one embodiment, the head spacemay provide the sole passageway through which fluid is transferred fromthe purging tube 5463 to the reduced-pressure cavity 5421. In thisembodiment, no interlumen channels 5440 may be present in the manifold5415 and no end cap may be placed on an end of the purging tube 5463. Inanother example, the end cap 5470 may be placed on an end of the purgingtube 5463 so that the interlumen channels 5440 provide the solepassageways through which fluid is transferred from the purging tube5463 to the reduced-pressure cavity 5421.

Referring primarily to FIG. 47, a primary manifolds 5486, which may anymanifold disclosed herein, may be used in conjunction with a secondarymanifold 5488. In FIG. 47, the secondary manifold 5488 includes atwo-layered felted mat. The first layer of the secondary manifold 5488is placed in contact with a bone tissue site 5489 that includes a bonefracture 5490 or other defect. The primary manifold 5486 is placed incontact with the first layer, and the second layer of the secondarymanifold 5488 is placed on top of the primary manifold 5486 and firstlayer. The secondary manifold 5488 facilitates fluid communicationbetween the primary manifold 5486 and the bone tissue site 5489, yetprevents direct contact between the bone tissue site 5489 and theprimary manifold 5486.

Preferably, the secondary manifold 5488 is bioabsorbable, which allowsthe secondary manifold 5488 to remain in situ following completion ofreduced-pressure treatment. Upon completion of reduced-pressuretreatment, the primary manifold 5486 may be removed from between thelayers of the secondary manifold 5488 with little or no disturbance tothe bone tissue site 5489. In one embodiment, the primary manifold 5486may be coated with a lubricious material or a hydrogel-forming materialto ease removal from between the layers.

The secondary manifold 5488 preferably serves as a scaffold for newtissue growth. As a scaffold, the secondary manifold 5488 may becomprised of at least one material selected from the group of polylacticacid, polyglycolic acid, polycaprolactone, polyhydroxybutyrate,polyhydroxyvalerate, polydioxanone, polyorthoesthers, polyphosphazenes,polyurethanes, collagen, hyaluronic acid, chitosan, hydroxyapatite,calcium phosphate, calcium sulfate, calcium carbonate, bioglass,stainless steel, titanium, tantalum, allografts, and autografts.

The purging function of the reduced-pressure delivery systems in FIGS.30-32, 36, 39, and 40 may be employed with any of the manifoldsdescribed herein. The ability to purge a manifold or a conduitdelivering reduced pressure prevents blockages from forming that hinderthe administration of reduced pressure. These blockages typically formas the pressure near the tissue site reaches equilibrium and egress offluids around the tissue site slows. It has been found that purging themanifold and reduced-pressure conduit with air for a selected amount oftime at a selected interval assists in preventing or resolvingblockages. For example, purging the manifold may prevent blockagescaused by fibrin.

More specifically, air is delivered through a second conduit separatefrom a first conduit that delivers reduced pressure. An outlet of thesecond conduit is preferably proximate to the manifold or an outlet ofthe first conduit. While the air may be pressurized and “pushed” to theoutlet of the second conduit, the air is preferably drawn through thesecond conduit by the reduced pressure at the tissue site. It has beenfound that delivery of air for two (2) seconds at intervals of sixty(60) seconds during the application of reduced pressure is sufficient toprevent blockages from forming in many instances. This purging scheduleprovides enough air to sufficiently move fluids within the manifold andfirst conduit, while preventing the introduction of too much air.Introducing too much air, or introducing air at too high of an intervalfrequency will result in the reduced-pressure system not being able toreturn to the target reduced pressure between purge cycles. The selectedamount of time for delivering a purging fluid and the selected intervalat which the purging fluid is delivered will typically vary based on thedesign and size of system components (e.g., the pump, tubing, etc.).However, purging fluid, such as air, should be delivered in a quantityand at a frequency that is high enough to sufficiently clear blockageswhile allowing the full target pressure to recover between purgingcycles.

Referring primarily to FIG. 48, in one illustrative embodiment, areduced-pressure delivery system 5491 includes a manifold 5492 fluidlyconnected to a first conduit 5493 and a second conduit 5494. The firstconduit 5493 is connected to a reduced-pressure source 5495 to providereduced pressure to the manifold 5492. The second conduit 5494 includesan outlet 5496 positioned in fluid communication with the manifold 5492and proximate an outlet of the first conduit 5493. The second conduit5494 is fluidly connected to a valve 5497, which is capable of allowingcommunication between the second conduit 5494 and the ambient air whenthe valve 5497 is placed in an open position. The valve 5497 is operablyconnected to a controller 5498 that is capable of controlling theopening and closing of the valve 5497 to regulate purging of the secondconduit with ambient air to prevent blockages within the manifold 5492and the first conduit 5493.

It should be noted that any fluid, including liquids or gases, could beused to accomplish the purging techniques described herein. While thedriving force for the purging fluid is preferably the draw of reducedpressure at the tissue site, the fluid similarly could be delivered by afluid delivery means similar to that discussed with reference to FIG. 9.

Referring primarily to FIGS. 49-52, a reduced-pressure deliveryapparatus 5800 is shown according to an illustrative embodiment. Thereduced-pressure treatment apparatus 5800 includes a manifold 5815, atransition region 5829, and a delivery tube 5825. The reduced-pressuretreatment apparatus 5800 delivers reduced pressure from areduced-pressure source, such as reduced-pressure source 5495 in FIG.48, to a subcutaneous tissue site through slits 5831. Thereduced-pressure treatment apparatus 5800 also includes a purgingfunction that helps to prevent blockages from forming in the manifold5815.

Although not shown in FIGS. 49-52, the manifold 5815 may include atleast one purging lumen operable to deliver a fluid, such as a gas orliquid, to a distal portion of the manifold 5815. The manifold 5815 mayalso include at least one reduced-pressure lumen operable to deliverreduced pressure to a subcutaneous tissue site via the slits 5831. Theat least one reduced-pressure lumen may terminate at the slits 5831,which provide an opening though which reduced pressure may be applied toa subcutaneous tissue site. In addition, the manifold 5815 may includeone or more interlumen channels that fluidly interconnect anycombination of the at least one reduced-pressure lumen, the at least onepurging lumen, and the slits 5831. In one embodiment, the slits 5831 areparallel to the at least one reduced-pressure lumen (not shown) and theat least one purging lumen (not shown). The at least one purging lumen,reduced-pressure lumen, and interlumen channel are shown in furtherdetail in FIGS. 53-55.

The manifold 5815 is adapted to be inserted for placement at asubcutaneous tissue site. In the embodiment of FIGS. 49-52, the manifold5815 has an flattened shape to facilitate the positioning of themanifold 5815 at a subcutaneous tissue site. In particular, the manifold5815 has flat side 5885 and opposing flat side 5886, as well as curvedside 5887 and opposing curved side 5888. In other examples, each of flatsides 5885 and 5886 and curved sides 5887 and 5888 may be flat, curved,or other shape. The width 5890 of the manifold 5815 is greater than theheight 5891 of the manifold 5815, which provides the manifold 5815 withflattened shape. However, the width 5890 may also be equal to or lessthan the height 5891.

The manifold 5815 may be composed of any material capable of beingplaced at a subcutaneous tissue site. In one example, the manifold 5815resists collapse when reduced pressure is applied through the manifold5815. Such resistance may be provided, at least in part, by thestructure of the manifold 5815, as well as the material from which themanifold 5815 is made. For example, the hardness of the material fromwhich the manifold 5815 is made may be adjusted such that the manifold5815 resists collapse when reduced pressure is applied through themanifold 5815. In one embodiment, the manifold 5815 may be composed ofsilicone, such as medical grade silicone. In another embodiment, themanifold 5815 may be composed of thermoplastic siliconepolyetherurethane.

The facilitate the placement of the manifold 5815 at a subcutaneoustissue site, the manifold 5815 may be coated with a lubricant, which maybe biocompatible or synthetic. The lubricant may facilitate percutaneousinsertion of the manifold 5815, as well as subcutaneous movement of themanifold 5815. In one example, the manifold 5815 is coated with eitheror both of heparin or parylene.

The flat side 5885 of the manifold 5815 includes slits 5831. The slits5831 are located on a distal portion of the manifold 5815. Although themanifold 5815 is shown to have three slits 5831, the manifold 5815 mayhave any number of slits, such as one slit. The slits 5831 extend to thedistal end of the manifold 5815. In one example, the slits 5831 mayextend across a majority of the length 5894 of the manifold 5815. Inanother example, the slits 5831 may extend across the entire length 5894of the manifold 5815.

Each of the slits 5831 are located on a single side, in particular theflat side 5885, of the manifold 5815. However, the slits 5831 may belocated on more than side of the manifold 5815. For example, all of thesides of the manifold 5815 may include one or more slits. The slits 5831may be parallel to one another, and each has the same length. However,the slits 5831 may have any orientation relative to one another. Forexample, a portion of the slits 5831 may be perpendicular to anotherportion of the slits 5831. Also, the slits 5831 may have non-uniformlengths, including an example in which each of the slits 5831 havedifferent lengths.

The manifold 5815 may also include an end cap 5870 that is attachable toan end of the manifold 5815 to form a head space, such as head space2171 in FIG. 31. The end cap 5870 may be permanently or removablyattached to the manifold 5815. The head space may accumulate fluid fromthe at least one purging lumen prior to the fluid being drawn via the atleast one reduced-pressure lumen.

The reduced-pressure treatment apparatus 5800 also includes thereduced-pressure delivery tube 5825. The delivery tube 5825 is in fluidcommunication with the manifold 5815. In one embodiment, the deliverytube 5825 delivers reduced pressure to the at least one reduced-pressurelumen and fluid, such as gas or liquid, to the at least one purge lumen.The delivery tube 5825 may have any cross-sectional shape, such as acircular, elliptical, polygonal, or irregular cross-sectional shape.

The reduced-pressure treatment apparatus 5800 also includes thetransition region 5829 disposed between the delivery tube 5825 and themanifold 5815. In one example, the transition region 5829 facilitatesfluid communication between the delivery tube 5825 and the manifold5815. One end 5895 may be sized to fit the delivery tube 5825, while theother end 5896 may be adapted to fit the manifold 5815.

Referring primarily to FIGS. 53 and 54, cross-sectional views of themanifold 5815 are shown according to an illustrative embodiment. Inparticular, FIG. 53 is a cross-sectional view of the manifold 5815 takenalong line 53-53 in FIG. 49. FIG. 54 is a cross-sectional view of themanifold 5815 taken along line 54-54 in FIG. 49.

The manifold 5815 includes reduced-pressure lumens 6321 to transferreduced pressure from a reduced-pressure source, such asreduced-pressure source 5495 in FIG. 48. The reduced-pressure lumens6321 deliver reduced pressure from a reduced-pressure source to a tissuesite, or any portion of the manifold 5815. The reduced-pressure lumens6321 may have any cross-sectional shape, including a circular,elliptical, flattened, irregular, or polygonal cross-sectional shape. Inone example, the material from which the manifold 5815 is made may beflexible, causing the cross-sectional shape of the reduced-pressurelumens 6321 to vary depending on fluid flow through the lumens, as wellas other factors. In addition, although FIG. 54 shows the manifold 5815to have three reduced-pressure lumens 6321, the manifold 5815 may haveany number of reduced-pressure lumens depending on the particularimplementation.

As the reduced-pressure lumens 6321 extend toward the distal end of themanifold 5815, the reduced-pressure lumens 6321 may gradually opentoward flat side 5885 to become the slits 5831. In this manner, each ofthe reduced-pressure lumens 6321 may terminate at a respective slit5831. Thus, at least one wall of each of the reduced-pressure lumens6321 may be contiguous with a wall of a respective slit. The number ofreduced-pressure lumens 6321 is equal to the number of slits 5831 in themanifold 5815.

Reduced pressure from a reduced-pressure source may be delivered to atissue site via the slits 5831. Each the slits 5831 allow fluidcommunication between the reduced-pressure lumens 6321 and a spaceoutside of the manifold 5815, such as a subcutaneous tissue site. Inaddition to permitting the transfer of reduced pressure from thereduced-pressure lumens 6321 to a tissue site, the slits 6331 may alsoallow exudate or other fluid from the tissue site to enter thereduced-pressure lumens 6321. The orientation of the slits 6331 relativeto the reduced-pressure lumens 6321, including, in some cases, aperpendicular orientation, may also help prevent soft tissue fromentering the reduced-pressure lumens 6321, thereby preventing blockagesand soft tissue damage.

The manifold 5815 also includes purging lumens 6263. Although themanifold 5815 is shown to have four purging lumens 6263, the manifold5815 may have any number of purging lumens. The purging lumens 6263,which are another non-limiting embodiment of the second conduit 2163 inFIGS. 30 and 31, are operable to deliver a fluid to a distal portion ofthe manifold 5815, including the end of the manifold 5815. The purginglumens 6263 may also deliver a fluid to the tissue space around themanifold 5815. The fluid delivered by the purging lumens 6263 may be agas, such as air, or a liquid. In one embodiment, one or more of thepurging lumens 6263 may be a sensing lumen. The reduced pressure at asubcutaneous tissue site may be detectable using the one or more sensinglumens.

The purging lumens 6263 may have any cross-sectional shape, including ancircular, elliptical, flattened, irregular, or polygonal cross-sectionalshape. In one example, the material from which the manifold 5815 is mademay be flexible, causing the cross-sectional shape of the purging lumens6263 to vary depending on fluid flow through the lumens.

The manifold 5815 includes interlumen channel 6240. The interlumenchannel 6240 fluidly connects, or otherwise provides fluid communicationbetween the purging lumens 6263 and either or both of thereduced-pressure lumens 6321 and the slits 5831. In one example, thereduced-pressure lumens 6321 draw purging fluid from the purging lumens6263 via the interlumen channel 6240. In another example, positivepressure in the purging lumens 6263 forces the fluid from the purginglumens 6263 to the reduced-pressure lumens 6321 via the interlumenchannel 6240. The positive pressure in the purging lumens 6263 may besupplied by a positive pressure source.

The manifold 5815 may include any number of interlumen channels, such asinterlumen channel 6240. For example, the manifold 5815 may include twoor more interlumen channels that are located at any point along thelength 5894 of the manifold 5815. In one non-limiting example, theinterlumen channels 6240 may be uniformly or non-uniformly spaced apartfrom one another. In another non-limiting example, the interlumenchannels 6240, or a number of the interlumen channels 6240, may becloser to one another at designated portions of the manifold 5815, suchas the portion of the manifold 5815 that includes slits 5831. In anothernon-limiting example, all of the interlumen channels 6240 may be locatedat the portion of the manifold 5815 that includes slits 5831. The numberof interlumen channels may control the rate of fluid being transferred,or the cross-flow, from the purging lumens 6263 to the reduced-pressurelumens 6321. The inclusion of two or more interlumen channels 6240 mayallow continued fluid communication between the purging lumens 6263 andthe reduced-pressure lumens 6321 in the event that one or more of theinterlumen channels becomes blocked or occluded by fibrin or othermaterials.

In another example, the transfer of fluid from the purging lumens 6263to the reduced-pressure lumens 6321 may occur via the head space that isformed by coupling an end of the manifold 5815 to the end cap 5870 inFIGS. 49-52. In one embodiment, the head space may provide the solepassageway through which fluid is transferred from the purging lumens6263 to the reduced-pressure lumens 6321. In this embodiment, nointerlumen channel 6240 may be present in the manifold 5815.

Referring primarily to FIGS. 55 and 56, cross-sectional views of thereduced-pressure treatment apparatus 5800 are shown according to anillustrative embodiment. In particular, FIG. 55 is a cross-sectionalview of the transition region 5829 as shown from the perspective ofcross-sectional indicator 56 in FIG. 49. FIG. 56 is a cross-sectionalview of the delivery tube 5825 as shown from the perspective ofcross-sectional indicator 56 in FIG. 49.

The delivery tube 5825 includes fluid delivery lumens 6430 that maydeliver fluid to the purging lumens 6263 in FIGS. 53 and 54. Thedelivery tube 5825 also includes reduced-pressure delivery lumens 6428that may deliver reduced pressure to the reduced-pressure lumens 6321,as well as other parts of the manifold 5815 and an adjacent tissue site.

The number of purging lumens 6263 in the manifold 5815 may exceed thenumber of fluid delivery lumens 6430 in the delivery tube 5825. Also,the number of reduced-pressure lumens 6321 in the manifold 5815 mayexceed the number of reduced-pressure delivery lumens 6428 in thedelivery tube 5825. The number of lumens increases from the deliverytube 5825 to the manifold 5815 in this manner at the transition region5829, which acts as the interface between the delivery tube 5825 and themanifold 5815.

In one embodiment, the transition region 5829 includes at least onecavity. In one example, the fluid delivery lumens 6430 may be in fluidcommunication with the purging lumens 6263 via the cavity. In thisexample, the fluid delivery lumens 6430 may be coupled, or otherwisefluidly connected, to an end of the cavity that is nearer the deliverytube 5825. The purging lumens 6263 may be coupled, or otherwise fluidlyconnected, to an end of the cavity that is nearer the manifold 5815.Providing a cavity in this manner permits the number of the fluiddelivery lumens 6430 and the purging lumens 6263 to be varied whilestill maintaining fluid communication between them.

In another example, the reduced-pressure delivery lumens 6428 may be influid communication with the reduced-pressure lumens 6321 via thecavity. In this example, the reduced-pressure delivery lumens 6428 maybe coupled, or otherwise fluidly connected, to an end of the cavity thatis nearer the delivery tube 5825. The reduced-pressure lumens 6321 maybe coupled, or otherwise fluidly connected, to an end of the cavity thatis nearer the manifold 5815. Providing a cavity in this manner permitsthe number of the reduced-pressure delivery lumens 6428 and thereduced-pressure lumens 6321 to be varied while still maintaining fluidcommunication between them. In addition, the transition region mayinclude two cavities, one of which provides fluid communication betweenthe fluid delivery lumens 6430 and the purging lumens 6263, the other ofwhich provides fluid communication between the reduced-pressure deliverylumens 6428 and the reduced-pressure lumens 6321.

In another embodiment, the transition region 5829 includes one or morebranching or forking pathways that allow fluid communication between alesser number of fluid delivery lumens and a greater number of purginglumens. The transition region 5829 may also include one or morebranching or forking pathways that allow fluid communication between alesser number of reduced-pressure delivery lumens and a greater numberof reduced-pressure lumens.

Referring primarily to FIGS. 57 and 58, a reduced-pressure treatmentapparatus 6600 is shown according to an illustrative embodiment. Thereduced-pressure treatment apparatus 6600 includes a manifold 6615, atransition region 6629, and a delivery tube 6625. The reduced-pressuretreatment apparatus 6600 delivers reduced pressure from areduced-pressure source, such as reduced-pressure source 5495 in FIG.48, to a subcutaneous tissue site through slits 6631 (only one of whichis shown in FIGS. 57 and 58). The reduced-pressure treatment apparatus6600 also includes a purging function that helps to prevent blockagesfrom forming in the manifold 6615.

In contrast to the manifold 5815 in FIGS. 49-53, the manifold 6615 has asubstantially cylindrical shape, as well as a substantially circularcross-sectional shape. In other embodiments, the manifold 5815 may haveany cross-sectional shape, such as a substantially rectangular,substantially polygonal, substantially triangular, substantiallyelliptical, star, or irregular cross-sectional shape.

Referring primarily to FIG. 59, a cross-sectional view of the manifold6615 taken along line 59-59 in FIG. 57 is shown according to anillustrative embodiment. FIG. 59 shows the spatial orientation of thepurging lumens 6863 and the slits 6631.

In contrast to the slits 5831 in FIGS. 49, 52, and 53, the slits 6631are spaced at equal intervals around an outer surface of the manifold6615. In particular, the manifold 6615 includes four slits 6631 that arespaced at ninety degree intervals from one another. Also, an axis 6852formed by a first pair of slits is perpendicular to an axis 6854 formedby a second pair of slits. Although four slits 6631 are shown on themanifold 6615, the manifold 6615 may include any number of slits. Also,the slits 6631 may be spaced at non-uniform intervals from one another,or may all be located on a single side of the manifold 6615.

Each of the purging lumens 6863 is substantially pie-shaped. A pie shapemay include a triangle modified in that one or more sides is/are curved.In addition, the purging lumens 6863 are spaced at equal intervalsaround a central longitudinal axis 6856 of the manifold 6615. Each ofthe four purging lumens 6863 are located in a separate quadrant of themanifold 6615, and are spaced at ninety degree intervals from oneanother. An axis 6857 formed by a first pair of purging lumens isperpendicular to an axis 6858 formed by a second pair of purging lumens.Although four purging lumens 6863 are shown in the manifold 6615, themanifold 6615 may include any number of purging lumens. Also, thepurging lumens 6863 may be spaced at non-uniform intervals from oneanother.

Referring primarily to FIGS. 60 and 61, cross-sectional views of thereduced-pressure treatment apparatus 6600 are shown according to anillustrative embodiment. In particular, FIG. 60 is a cross-sectionalview of the transition region 6629 taken along line 60-60 in FIG. 57.FIG. 61 is a cross-sectional view of the delivery tube 6625 taken alongline 61-61 in FIG. 57.

The delivery tube 6625 includes fluid delivery lumen 6930 that maydeliver fluid to the purging lumens 6863 in FIGS. 59 and 60. Thedelivery tube 6625 also includes reduced-pressure delivery lumen 7028that may deliver reduced pressure to the reduced-pressure lumens 6921,as well as other parts of the manifold 6615 and an adjacent tissue site.The reduced-pressure delivery lumen 7028 is shown to have a largerdiameter than the fluid delivery lumen 6930, although each of theselumens may have any size relative to one another.

The number of lumens increases from the delivery tube 6625 to themanifold 6615 at the transition region 6629, which acts as the interfacebetween the delivery tube 6625 and the manifold 6615.

Referring primarily to FIGS. 62 and 63, the application of a manifold7115 to a subcutaneous tissue site 7105 is shown according to anillustrative embodiment. The manifold 7115 includes a felt envelope 7197that may cover at least a portion of the outer surface of the manifold7115 and may serve as a second manifold, e.g., second manifold 5488 inFIG. 47. In one example, the felt envelope 7197 may cover a majority orall of the outer surface of the manifold 7115. The felt envelope 7197may help to prevent soft tissue from blocking openings, apertures, orslits in the manifold 7115, and may help to prevent tissue damage whenthe manifold 7115 is removed from the subcutaneous tissue site 7105.

In one embodiment, a method for applying reduced pressure to thesubcutaneous tissue site 7105 includes applying the manifold 7115 to thesubcutaneous tissue site 7105. The manifold 7115 may be percutaneouslyinserted into a patient, and the manifold 7115 may be positionedadjacent to or abutting the subcutaneous tissue site 7105. Thesymmetrical design of the manifold included in at least a portion of theillustrative embodiments may facilitate the implantation of the manifoldin any orientation.

In the example in which the subcutaneous tissue site 7105 includes adefect, such as a fracture, a scaffold 7196 may be positioned at thedefect site to improve healing and tissue generation characteristics.The scaffold 7196 may be adjoined to the subcutaneous tissue site 7105using a tibial nail 7198.

The delivery tube 7125 may be used to facilitate placement of themanifold 7115 at the subcutaneous tissue site 7105. The delivery tube7125 may be coupled to a reduced-pressure source via apurge/reduced-pressure connector 7195.

In one embodiment, a method of manufacturing an apparatus for applyingreduced pressure to the subcutaneous tissue site 7105 includes formingmanifold 7115. The method may also include providing the delivery tube7125 and coupling the delivery tube 7125 to the manifold 7115 such thatthe delivery tube 7125 is in fluid communication with the manifold 7115.

Referring now primarily to FIGS. 64-66, another illustrative embodimentof a reduced-pressure delivery apparatus 7200 is presented. Thereduced-pressure delivery apparatus 7200 includes a manifold 7202 havinga longitudinal manifold body 7204 and having a first side 7206 and asecond, tissue-facing side 7208. The reduced-pressured deliveryapparatus 7200 delivers reduced pressure from a reduced pressure source,such as reduced-pressure source 5495 in FIG. 49, to a subcutaneoustissue site, such as a bone or more particularly a vertebrae or multiplevertebra, through a plurality of apertures 7210 formed on the second,tissue-facing side 7208 of the longitudinal manifold body 7204. Theplurality of apertures 7210 may be further distributed or manifolded bya plurality of manifolding surface features 7212, such as a plurality ofrecesses 7214 or rounded grooves. The plurality of recesses 7214 may beasymmetrical to facilitate percutaneous removal.

The plurality of apertures 7210 are associated with the plurality ofmanifolding surface features 7212, which help distribute the reducedpressure. The plurality of apertures 7210 fluidly couple the pluralityof manifold surface features 7212 to an evacuation lumen orreduced-pressure lumen 7216 by conduits 7218. The reduced-pressure lumen7216 may be one or a plurality of conduits for delivering reducedpressure and removing fluids. The reduced-pressure lumen 7216 runs thelongitudinal length of the longitudinal manifold body 7204. Thelongitudinal manifold body 7204 also contains at least one purging lumenor conduit 7220. The one or more purging lumens 7220 also run thelongitudinal length of the longitudinal manifold body 7204. At a distalend 7222 of the manifold 7202 is an end cap 7224. The end cap 7224 maybe formed integrally as part of the longitudinal manifold body 7204.

The end cap 7224 provides head space (not shown) that allows the purgingfluid within the one or more purging lumens 7220 to be fluidly coupledto the reduced-pressure lumen 7216. The first side 7206 of thelongitudinal manifold body 7204 near the distal end 7222 may also have aplurality of ridges 7226 and second plurality of recesses 7228.

A proximal end 7230 out of the longitudinal manifold body 7204 may havea connector 7232 to facilitate connection with a reduced-pressuredelivery tube or conduit 7234. The reduced-pressure delivery tube 7234may be a multi-lumen conduit that provides reduced pressure from thereduced-pressure source to the reduced-pressure lumen 7216 of themanifold 7202 and provides a purging fluid to the one or more purginglumens 7220.

In operation, the reduced-pressure delivery apparatus 7200 is used in amanner analogous to the embodiments previously presented. Thus, thesecond, tissue-facing side 7208 of the manifold 7202 is positionedproximate the tissue site and reduced pressure is supplied. The reducedpressure is delivered to the tissue site through the apertures 7210 andthe manifolding surface features 7212. A purging fluid, e.g., air, isused to help remove or avoid blocking of the reduced pressure lumen 7216and to prevent hydrostatic equilibrium.

Referring now primarily to FIGS. 67-70, another illustrative embodimentof a reduced-pressure delivery apparatus 7300 is presented. Thereduced-pressure delivery apparatus 7300 includes a manifold 7302 havinga longitudinal manifold body 7304, which has a first side 7306 and asecond, tissue-facing side 7308. The manifold 7302 may be formed byinjection molding. Injection molding of the manifold 7302 may help toavoid portions breaking or being otherwise at risk of being left in thepatient's body. The manifold 7302 may also be extruded into parts andthen bonded or otherwise coupled to form an integral unit.Alternatively, the manifold 7302 may be extruded and then undergo asecondary controlled melt “tipping” process to form an integral unit.The manifold 7302 may be made from a flexible or semi-rigid material.For example, the manifold 7302 may be made from any medical-gradepolymer, such as polyurethane, etc. In one embodiment, the manifold 7302is made from a material with a stiffness of approximately 80 Shore A,but other stiffnesses may be used. A coating may be added to themanifold 7302 to avoid material buildup on the manifold 7302.

A plurality of apertures 7310 are formed on the second, tissue-facingside 7308 of the longitudinal manifold body 7304 for providing reducedpressure to a subcutaneous tissue site, such as a bone. While theapertures are shown in a symmetrical space pattern, it should beunderstood that the apertures may be formed with any pattern or with arandom placement. A plurality of manifold surface features 7312 areformed on the second, tissue-facing side 7308. The plurality of manifoldsurface features 7312 may include a plurality of standoffs or offsets7314. The plurality of offsets 7314 may be formed integrally with orcoupled to the second, tissue-facing side 7308 of the longitudinalmanifold body 7304. The offsets 7314 may be any surface feature creatingeffective flow channels between the second, tissue-facing side 7308 andthe tissue site. The surface features 7312 may detach from the manifoldbody 7304 when the manifold 7302 is percutaneously removed, and thesurface features 7312 may be bioresorbable.

The apertures 7310 are fluidly coupled to reduced-pressure lumen 7316formed in the longitudinal manifold body 7304. The reduced-pressurelumen 7316 is fluidly coupled to the apertures 7310 by a plurality ofconduits 7318. The reduced-pressure lumen 7316 runs the length 7319 ofthe longitudinal manifold body 7304. The longitudinal manifold body 7304is also formed with one or more purging lumens 7320 which also run thelength 7319 of the longitudinal manifold body 7304. While theillustrative embodiment shows two purge lumens 7320, it should beunderstood that any number may be used. Additionally, the two purgelumens 7320 are shown symmetrically spaced about the reduced-pressurelumen 7316, and while the symmetric orientation of the two purge lumen7320 does enhance performance in that the performance is not degradatedby different orientations, other orientations may be used. Additionallumens, such as a pressure sensing lumen, may be included within thelongitudinal manifold body 7304.

On the distal end 7322 of the longitudinal manifold body 7304 an end cap7324 is formed or coupled. The end cap 7324 is formed with a headerspace 7325 that allows the one or more purging lumens 7320 to be fluidlycoupled to the reduced-pressure lumen 7316. The end cap 7324 is formedintegrally to the or as part of the longitudinal manifold body 7304 andthus, avoids the risk of the end cap becoming dislodged during removalfrom the patient's body.

At the proximal end 7330 of the longitudinal manifold body 7304, aconnector 7332 may be coupled to provide easy connection with areduced-pressure delivery tube or conduit 7334, which in turn is fluidlycoupled to a reduced pressure source and also a source of a purgingfluid or liquid. The reduced-pressure delivery tube 7334 may be amulti-lumen conduit that delivers reduced pressure to thereduced-pressure lumen 7316 and provides the purging fluid to the one ormore purging lumens 7320. The purging fluid may be, for example,atmospheric air.

The longitudinal manifold body 7304 has the length 7319 and a width7336. Typically a treatment area 7338, which has a longitudinal lengthof 7340 is formed close to the distal end 7322. The longitudinalmanifold body 7304 typically has an aspect ratio, which is the length7319 divided by the width 7336, that is greater than five, and typicallygreater than 10 or even 20 or more. In one embodiment for a spinalapplication, the longitudinal length 7340 of the treatment area 7338 isin the range of about 60 to 80 millimeters, but it should be understoodthat any dimension may be used depending on the application involved.

In one illustrative, non-limiting embodiment, the effective diameter ofthe lateral cross section of the longitudinal manifold body 7304 iseight millimeters and in another illustrative embodiment is elevenmillimeters, but it should be understood that while specific dimensionsare given for an example, any size effective diameter may be used. Itshould also be noted that although a slightly elliptical or triangularshape is presented, the cross sectional shape of the longitudinalmanifold body may be any of those previously mentioned or even irregularor other shapes.

In operation, the manifold 7302 may be inserted surgically or usingminimally invasive surgery. Typically, the manifold 7302 would beremoved percutaneously or in one embodiment may be bio-absorbable andleft in place.

The administration of reduced-pressure tissue treatment to a tissue sitein accordance with the systems and methods described herein may beaccomplished by applying a sufficient reduced pressure to the tissuesite and then maintaining that sufficient reduced pressure over aselected period of time. Alternatively, the reduced pressure that isapplied to the tissue site may be cyclic in nature. More specifically,the amount of reduced pressure applied may be varied according to aselected temporal cycle. Still another method of applying the reducedpressure may vary the amount of reduced pressure randomly. Similarly,the rate or volume of fluid delivered to the tissue site may beconstant, cyclic, or random in nature. Fluid delivery, if cyclic, mayoccur during application of reduced pressure, or may occur during cyclicperiods in which reduced pressure is not being applied. While the amountof reduced pressure applied to a tissue site will typically varyaccording to the pathology of the tissue site and the circumstancesunder which reduced-pressure tissue treatment is administered, thereduced pressure will typically be between about −5 mm Hg and −500 mmHg, but more preferably between about −5 mm Hg and −300 mm Hg.

While the systems and methods of the present disclosure have beendescribed with reference to tissue growth and healing in human patients,it should be recognized that these systems and methods for applyingreduced-pressure tissue treatment can be used in any living organism inwhich it is desired to promote tissue growth or healing. Similarly, thesystems and methods of the present disclosure may be applied to anytissue, including, without limitation, bone tissue, adipose tissue,muscle tissue, neural tissue, dermal tissue, vascular tissue, connectivetissue, cartilage, tendons, or ligaments. While the healing of tissuemay be one focus of applying reduced-pressure tissue treatment asdescribed herein, the application of reduced-pressure tissue treatment,especially to tissues located beneath a patient's skin, may also be usedto generate tissue growth in tissues that are not diseased, defective,or damaged. For example, it may be desired to use the percutaneousimplantation techniques to apply reduced-pressure tissue treatment togrow additional tissue at a tissue site that can then be harvested. Theharvested tissue may be transplanted to another tissue site to replacediseased or damaged tissue, or alternatively the harvested tissue may betransplanted to another patient.

It is also important to note that the reduced-pressure deliveryapparatuses described herein may be used in conjunction with scaffoldmaterial to increase the growth and growth rate of new tissue. Thescaffold material could be placed between the tissue site and thereduced-pressure delivery apparatus, or the reduced-pressure deliveryapparatus could itself be made from bioresorbable material that servesas a scaffold to new tissue growth.

Although the present invention and its advantages have been disclosed inthe context of certain illustrative, non-limiting embodiments, it shouldbe understood that various changes, substitutions, permutations, andalterations can be made without departing from the scope of theinvention as defined by the appended claims. It will be appreciated thatany feature that is described in a connection to any one embodiment mayalso be applicable to any other embodiment.

We claim:
 1. A manifold for providing reduced pressure to a subcutaneoustissue site on a patient, the manifold comprising: a longitudinal bodyincluding at least one purging lumen and a reduced-pressure lumen, thelongitudinal body having a first side and a second side adapted to facethe tissue site; a plurality of manifolding surface features formed onthe second side of the longitudinal body; a plurality of aperturesformed in the longitudinal body on the second side, wherein theplurality of apertures fluidly couple the reduced-pressure lumen and theplurality of manifolding surface features; and an end cap disposed on adistal end of the longitudinal body and fluidly coupling thereduced-pressure lumen and the at least one purging lumen through aheader space in the end cap.
 2. The manifold of claim 1, wherein theplurality of manifolding surface features comprise a plurality ofrecesses.
 3. The manifold of claim 1, wherein the plurality ofmanifolding surface features comprise a plurality of offsets.
 4. Themanifold of claim 1, wherein the end cap is formed integrally with thelongitudinal body.
 5. The manifold of claim 1, wherein the longitudinalbody has an aspect ratio greater than
 10. 6. The manifold of claim 1,wherein the longitudinal body and the plurality of manifolding surfacefeatures comprise a bioreabsorbable material.
 7. The manifold of claim1, wherein the plurality of manifolding surface features arebioreabsorbable.
 8. The manifold of claim 1, wherein the plurality ofmanifolding surface features are detachable and are operable to detachwhen percutaneously removed from the patient.
 9. A system for treating asubcutaneous tissue site on a patient with reduced pressure, the systemcomprising: a reduced-pressure source; a manifold comprising: alongitudinal body having at least one purging lumen and areduced-pressure lumen, the longitudinal body having a first side and asecond-side adapted to face the tissue site, a plurality of manifoldingsurface features formed on the second side of the longitudinal body, aplurality of apertures formed in the longitudinal body on the secondside, wherein the plurality of apertures fluidly couple thereduced-pressure lumen and the plurality of manifolding surfacefeatures, and an end cap disposed on a distal end of the longitudinalbody and fluidly coupling the reduced-pressure lumen and the at leastone purging lumen through a header space in the end cap; and a reducedpressure delivery tube coupling the reduced-pressure source and themanifold.
 10. The system of claim 9, wherein the plurality ofmanifolding surface features comprise a plurality of recesses.
 11. Thesystem of claim 9, wherein the plurality of manifolding surface featurescomprise a plurality of offsets.
 12. The system of claim 9, wherein theend cap is formed integrally with the longitudinal body.
 13. The systemof claim 9, wherein the longitudinal body has an aspect ratio greaterthan
 10. 14. The system of claim 9, wherein the longitudinal body andthe plurality of manifolding surface features comprise a bioreabsorbablematerial.
 15. The system of claim 9, wherein the plurality ofmanifolding surface features are bioreabsorbable.
 16. The system ofclaim 9, wherein the plurality of manifolding surface features aredetachable and are operable to detach when percutaneously removed fromthe patient.